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Nipun Chopra 
THE MICRORNA-MEDIATED REGULATION OF PROTEINS IMPLICATED IN 
THE PATHOGENESIS OF ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder 
characterized by the post-mortem deposition of amyloid-beta (Aβ) containing neuritic 
plaques and tau-loaded tangles. According to the amyloid hypothesis, the generation of 
Aβ via the cleavage of Aβ precursor protein (APP) by β-APP site-cleaving enzyme 1 
(BACE1) is a causative step in the development of AD. Therefore, targeting the 
production and/or clearance of Aβ peptide (by Aβ-degrading enzymes such as 
Neprilysin) would help understand the disorder as well as serves as therapeutic potential 
to treat the disorder. MicroRNA are small, noncoding RNA capable of modulating 
protein expression by primarily targeting their 3’UTR. Therefore, identifying miRNA 
which target APP, BACE1 and Neprilysin (NEP) would elucidate the complicated 
regulatory mechanisms involved in protein turnover and provide novel drug targets. We 
identified miR-20b as a modulator of APP and soluble Aβ. We also identified the target 
site for miR-20b’s binding on the APP 3’UTR.  Further, miR-20b exerts influence on 
neuronal morphology, likely due to its APP reduction. We also identified miR-298 as a 
dual regulator of APP and BACE1 and confirmed miR-298’s targeting of both 3’UTRs. 
We also showed that miR-298 overexpression reduced levels of both soluble Aβ40 and 
Aβ42 peptides. Additionally, we identified two SNPs in proximity to the MIR298 gene, 
which are associated with AD-related biomarkers. Based on these results, we showed 
miR-298 targets a specific isoform of tau by putatively binding a non-canonical target 
site on the MAPT 3’UTR. Finally, the insertion of the NEP 3’UTR into a reporter vector 
v 
increases reporter expression; suggesting regulatory elements targeting the 3’UTR. We 
subsequently identified miR-216 as reducing NEP 3’UTR-mediated luciferase activity. 
We also measured levels of NEP protein in various mammalian tissue – such as rodent 
and human fetal tissue, and subsequently showed measurable Aβ levels in correlation 
with NEP expression. Therefore, herein, we have identified miRNA involved in the 
regulation of proteins implicated in the pathogenesis of AD. 
        Feng Zhou, Ph.D., Chair 
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Chapter 1: Introduction 
 Alzheimer’s disease (AD) is a progressive neurodegenerative condition affecting 
millions worldwide. AD is the most common form of dementia seen in the elderly 
population, comprising of about 70% of dementias in older adults, and is the 6th leading 
cause of death in the US 1,2. According to the latest report from the Alzheimer’s 
Association, currently 5.4 million Americans have AD, with 5.2 million of those being 
over the age of 65 (https://www.alz.org/documents_custom/2016-facts-and-figures.pdf). 
Notably, 1 out of 9 people over the age of 65, and 1 out of 3 people over the age of 85 
have AD. By 2050, this number is expected to rise to 14 million people. The expected 
rise in incidence of AD would have a significant impact on the society at large. Current 
estimates predict that the number of neurologists in 2025 and 2050 will not be sufficient 
to handle the marked increase in AD incidence 3. Along with the problems associated 
with AD itself, the disease is associated with other psychiatric problems in the elderly – 
such as depression 4,5, bipolar disorder 6, schizophrenia 7 and sleep alterations 8. AD is 
also considered to be a moderate risk for suicidality 9. Therefore, AD is expected to be a 
significant health and financial burden for the foreseeable future. 
 Interestingly, the incidence of the disorder varies greatly by geographical location 
10. The Asian-pacific populations have about a 3-5% prevalence of AD, with Japan being 
the highest in the region, at 11% 11-14. Usually migrant populations living in the USA 
show an increased prevalence of AD compared to similar populations living in their 
home countries 15,16 - a possible effect of the complex interplay of genes, diet, 
environmental factors, etc.  Interestingly, in terms of environmental factors, a meta-
analysis suggested that early-life rural living may pose an increased risk for AD onset17. 
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 The disease was first described by Alois Alzheimer in a seminal paper which was 
translated into English 18. Over the last 110 years, scientists have attempted to unravel the 
underlying mechanism of the disorder and to find a potential therapy to reverse the 
cognitive decline associated with the disorder. The progression of the disease was 
described in a seminal paper 19. Pathology first manifests in the transentorhinal area and 
then migrates to the neocortex and hippocampal structure. In later stages of the disorder, 
pathology affects cortical structures globally 20. Given the progression of the disease, it is 
not surprising that impaired cognitive and memory functions are hallmarks of the disease 
20. Unfortunately, there has not been much success in either elucidating the mechanism or 
finding a cure for AD. 
Genetics of AD 
 Approximately 10% of AD patients have an early onset AD (EOAD), with 
diagnosis occurring between 45 and 60 years of age, whereas, the vast majority of AD 
diagnosis occurs after the age of 65 and is referred to as late-onset AD (LOAD)21 . 
Mutations in the APP, Presenlin-1(PSEN1) and Presenelin-2 (PSEN2) genes are involved 
in the onset of EOAD 22-27 whereas APOE ε4 and TREM2 are widely accepted to be risk 
factors for LOAD 28-30, although GWAS studies have implicated loci on other genes such 
as phosphatidyl binding clathrin assembly protein (PICALM), sortilin-related receptor L 
(SORL1), ATP-binding cassette, sub family A member 7 (ABCA7) etc 31-35. Of great 
interest has been the study of single nucleotide polymorphisms (SNP)s in aforementioned 
genes as well as examining GWAS for SNPs in previously unexplored AD-related genes. 
An asset in this field is the emergence of the AD neuroimaging initiative (ADNI) which 
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allows for GWAS-derived identification of novel genes, SNPs, as well as possible 
associations with CSF biomarkers 36,37. 
The role of amyloid-beta precursor protein in AD 
The amyloid-beta precursor protein (APP) plays a central role in the “amyloid 
cascade hypothesis” 38 as it is the parent molecular from which the potentially toxic 
amyloid- beta- fragment (Aβ) is generated. The hypothesis by Hardy and Higgins posits 
Aβ upstream of the pathological changes and cognitive decline associated with AD. 
Additionally, mutations in the APP gene are associated with EOAD, which is also known 
as familial AD (FAD) 39-42. The APP gene is located on chromosome 21, which is why 
the inheritance of an extra copy of chromosome 21 (as seen in Down’s syndrome) is 
associated with cognitive decline43. The gene comprises 19 exons and can be 
alternatively spliced into multiple forms 44,45, the form most commonly expressed in the 
neurons codes for 695 amino acids, whereas the larger forms (APP751/770) are 
expressed in glia 46-48. APP is a single transmembrane protein implicated in a myriad of 
functions, 49 including cell adhesion50, neurite outgrowth 51 , apoptosis 52 and cell 
signaling. APP can undergo both homodimerization and heterodimerization. APP is post-
translationally modified by glycosylation, tyrosylation and phosphorylation 50,53. While 
APP knockout mice are viable, they show aberrant long term potentiation (LTP), 
impaired locomotor activity and reduced brain weight54-56 thereby confirming the 
important role of APP in normal brain development and function.  
 According to the Human Protein Atlas 57, a freely available database showing 
protein expression in various tissues and cell lines, APP expression is highest in the adult 
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human brain, but observable in most peripheral tissues. Very little APP expression was 
observed in lung or kidney tissues 57. To our knowledge a tissue-wide expression profile 
of APP has not been conducted in human fetal tissue or rat tissue.  
 APP protein paralogs, APP-like protein 1 (APLP1) and APP- like protein 2 
(APLP2) 58-60  have similar but not identical functional properties (Sambamurti et al., 
2002). Crucial to our discussion on AD, these APLPs lack the Aβ domain, and therefore 
have different properties after being processed by enzymes like BACE1 61. APLPs are 
expressed in species such as worms and flies, while APP itself is first observed 
evolutionarily in amphibians 61,62.  
 The processing of APP is important to the generation of Aβ. APP can be 
processed in two major pathways:  amyloidogenic and non-amyloidogenic s 63. Under the 
non-amyloidogenic pathway, APP is cleaved by alpha-secretase (α-secretase) followed 
by the  gamma-secretase (γ-secretase) complex (Figure1), liberating soluble APP α 
(sAPPα) 64 and a non-toxic 3 kDa protein (P3) fragment. SAPPα has been shown to 
involve  in neurogenesis, potentially by binding to anchoring proteins in the extracellular 
matrix 65as well as  a regulator of neural stem cell proliferation 66. SAPPα has also been 
implicated to protect against glutamate neurotoxicity in vitro 67,68. 
 In the non-amyloidogenic pathway during AD, due to a not yet understood reason, 
APP is preferentially cleaved by β-site APP cleaving enzyme-1 (BACE1) instead of α-
secretase which liberates a soluble β-APP fragment (sAPPβ) and an APP-CTFβ fragment. 
sAPPβ is linked to potentially neurotoxic effects of its own, including a reduction in cell 
adhesion, and potentiating cell death by binding to the DR6 receptor 69,70. The γ-secretase 
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complex then acts on the APP-CTFβ fragment to generate APP Intracellular domain 
(AICD) and the potentially toxic Aβ fragments.  
The role of β-APP site-cleaving enzyme 1 in AD 
 Beta-Site APP-cleaving enzyme-1 (BACE1) or -secretase is considered to be the 
rate-limiting enzyme in the generation of Aβ. BACE1 was discovered as the titular β-
secretase independently by four different laboratories71-74 and has been the focus of 
current AD therapeutics. BACE1 is first translated as a proenzyme but is significantly 
more active after removal of its prodomain and transport into early endosomes 75. The 
mature BACE1 protein is 501 amino acid in length with a mass of ~70 kDa 71,74.  
 BACE1 is capable of cleaving multiple substrates including APP 71, Neuregulin-1 
(NRG1) 76, beta-2 subunit of voltage-gated sodium channels 77, membrane-bound alpha-
2,6-sialyltransferase (ST6Gal1) 78,79, and many other possible substrates 80. Evidence 
suggests that BACE1’s activity is strongest at an acidic pH 71,75, which is why it is 
believed to be active in early endosomes. However, it is important to note in subcellular 
terms, BACE1 is also detected on the plasma membrane, from where it can be 
endocytosed and recycled into endosomes 75, as well as evidence suggesting BACE1 
localization in lipid rafts in the brain81.  
 The protein has a homolog, BACE2, found on chromosome 21, with which is 
shares about 68% homology 82.  BACE2 is lowly expressed in the brain, but highly 
expressed in peripheral tissues such as colon, kidney and pancreas. 83 BACE2 cleaves 
APP within the Aβ domain and is considered to be non-amyloidogenic 84. It was 
experimentally determined that BACE1 from branchiostoma was able to cleave APP at 
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the Aβ site, implicating a strong conservation of BACE1 from an evolutionary 
perspective 62. However, it is important to note that BACE1 evolution far preceded the 
evolution of the Aβ domain, thereby implicating BACE1 in a variety of other roles 
independent of APP processing 62. 
 These functions include the cleavage of aforementioned substrates, as well as 
larger phenotypical roles, such as myelination in the CNS 85; likely due to its cleavage of 
NRG1. Data from BACE1 knock out mice suggest that they are viable, but show 
impaired myelination and an increased seizure rate 85,86. 
 In terms of tissue-wide expression, BACE1 is found expressed at high levels in 
the human and rat brain 83. The human protein atlas suggests that BACE1 is highly 
expressed in adult human kidney, gastrointestinal tissue and endocrine tissue 57. Previous 
work has shown that BACE1 mRNA is increased in AD brain, as a function of Braak 
stage in the superior occipital gyrus, medial temporal gyrus and superior parietal gyrus 87. 
Work in our lab confirms that BACE1 protein levels in the brain are increased when 
comparing AD vs. non-AD patients 88. 
 To our knowledge, expression patterns for BACE1 expression in human fetal 
tissues remains unexplored. 
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Figure 1: Diagrammatic representation of the cleavage of APP by BACE1 and γ-
secretase resulting in the generation of Aβ. Also shown in the degradation of Aβ by 
NEP – one of many Aβ degrading enzymes. 
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Biogenesis and role of amyloid-beta peptides in neurodegeneration and AD 
 In accordance with the amyloid hypothesis, Aβ is the causative factor underlying 
the onset and progression of AD 38,89,90, although the validity of this hypothesis has been 
questioned recently (For a review 91). Multiple lines of evidence link Aβ with AD and the 
onset of dementia. These include observations that Aβ is the major component of amyloid 
plaque in the brain 92-94 and the development of AD and increased Aβ deposition in 
patients with trisomy 21 95. 
 The generation of Aβ (lying partly within the transmembrane domain and partly 
in the extracellular domain of APP 96)  is a consequence of a cleavage of APP by BACE1, 
producing the C99 fragment, and then a subsequent cleavage by the γ-secretase complex 
liberating the Aβ fragment 97 (Figure 1). The γ-secretase complex comprises at least four 
different proteases, such as presenilins, nicastrin, Aph-1 and Pen-2, and is responsible for 
a promiscuous cleavage of APP, producing Aβ of 40 or 42 amino acids in length 98,99. 
Additional Aβ fragments have also been reported as a consequence of secondary cleavage 
by other secretases 100. 
 From a cellular standpoint, reports suggest that neurons, glia, fibroblasts as well 
as blood platelets are capable of releasing Aβ 101-103, which help in measuring levels of 
Aβ in the brain, CSF and blood/plasma.  
 The two Aβ fragments (Aβ40 and Aβ42) have different properties which are 
reportedly crucial to the onset of AD. Aβ42 tends to be more hydrophobic, 
amyloidogenic and toxic of the two species, and has the aggregative properties associated 
with neuritic plaque formation 104-108. In familial AD, it is suggested that more so than the 
9 
levels of the two Aβ fragments, a higher Aβ42/ Aβ40 ratio that results in plaque 
deposition 109. An interesting line of evidence suggests that Aβ40 may actually protect 
against AD onset and at low concentrations is involved in long-term potentiation (LTP) 
and normal memory processes 110-114.   
 While the mechanism underlying Aβ aggregation is still unclear, it is believed that 
as the concentration of Aβ40 and Aβ42 monomers increases, monomers change their 
conformation from an alpha-helical structure to beta-sheets, thereby increasing their 
aggregative properties 107,108.  The aggregation of these Aβ  monomers results in the 
productions of dimers, trimers, oligomers, fibrils and eventually plaque 115, even though 
the exact processes remains unclear. Many have also speculated a prion-like mechanism 
underlying the formation of amyloid fibrils and plaque 116,117, but this too remains 
controversial 117-120.  
 The mechanism of Aβ neurotoxicity also remains under investigation. 
Correlatively, it has been shown that Aβ oligomers invoke neurotoxicity and are 
increased in the brain of AD patients and are also detected in CSF and plasma from AD 
patients 121,122. Two potential mechanisms for this neurotoxicity are calcium toxicity and 
receptor-binding-mediated activation of intracellular cascades. Aβ is capable of forming 
cation permeable channels in the plasma membrane, thereby disrupting the well-regulated 
conductance properties which facilitate the electrochemical gradient 123-127.  It has also 
been shown that Aβ is able to bind various receptors such as lipoprotein-related peptide 1 
(LRP1), SorLA, various acetyolcholinergic receptors and nerve growth factor (NGF) 
receptor 114,128,129. While the signaling cascades propagating from binding of these 
receptors can vary, binding to the NGF receptor, in particular, can lead to neuronal death 
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129,130. Beyond its potential for toxicity, it has been shown that Aβ may set up a positive-
feedback loop for its own production by binding to the promoter of APP and BACE1 
131,132 , thereby leading to the production of more Aβ and further toxicity. 
 Given the toxicity associated with Aβ and the multitude of evidence linking it’s 
involvement in AD onset and progression, reducing Aβ levels is an important goal of AD 
therapies. We discuss the results of clinical trials attempting to reduce Aβ levels in a later 
section. 
Role of neprilysin in AD 
Perturbation of the homeostasis of Aβ-production and clearance can contribute to 
AD 133. In vitro studies have shown that once Aβ has been generated, it can be cleaved by 
many enzymes 134,135 136. In vivo and in vitro results have focused on NEP and Endothelin 
converting enzymes-1 and 2 (ECE1 and ECE2) 137-139. Given that NEP is associated with 
the extracellular surface of membranes 134, it is likely that it would be a major player in 
clearing amyloid beta plaques; both in the cytosol as well as in the extracellular domain.  
NEP is also called neutral endopeptidase (NEP), cluster of differentiation 10 
(CD10), common acute lymphoblastic leukemia antigen (CALLA), membrane metallo-
endopeptidase (MME). NEP is an integral membrane glycoprotein and a zinc-containing 
metallopeptidase 140,141 that has been implicated in the clearance of Aβ 142-144, and AD 
135,144-146. It can be argued that a reduction in NEP expression/activity would result in an 
increase in Aβ load. In support of this idea, NEP gene-disrupted mice produced high 
levels of Aβ 40 and Aβ 42 144,147. Conversely, but consistently to NEP’s predicted role, 
overexpression of NEP produced reduction in neuronal Aβ in cell culture models 148, in 
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drosophila 149, in mouse brains 150-152 and in neuronal human progenitor cells 153. 
Moreover, Takaki et al. (2000) suggested that aging may cause a down-regulation of NEP 
in the brain 154. Taken together, these results suggest that NEP has an important role in 
the clearance of Aβ required to prevent Aβ accumulation correlated with AD. 
The NEP gene comprises 24 exons and produces three splice variants in rats and 
four splice variants in human 144,155-157. NEP, which is a 750 amino acid protein (Figure 
2), has two hydrophilic domains (extracellular and cytosolic), a single hydrophobic 
domain and a signal peptide, while the ATG start codon is situated on Exon 3 140. Within 
the region spanning the active site domain, are three sites to which Zn can bind (Figure 
2). Also present are nine sulfide bonding sites and five glycosylation sites which 
contribute to the quaternary structure and post-translational modification of this protein 
respectively (Figure 2). The NEP gene cleaves Aβ at the Gly9-Tyr10 position and is 
capable of clearing both monomeric and oligomeric forms of AB 143,145,158. The tissue 
distribution of NEP has also been studied using immunohistochemistry of mice brains.  
NEP levels are highest in the kidney, followed by lungs and brain 159. Fukami et al. 
(2002) showed that mice overexpressing human-type APP reveal high NEP expression in 
regions such as substantia nigra and caudate putamen, a moderate expression in the 
hippocampus and neocortex and a low expression in the cerebellum 159. Interestingly, 
cerebellar levels in ‘steady-state’ conditions reveal a different distribution – cerebellar 
NEP expression seems to be the highest, followed by cortical expression, and 
hippocampal expression 158. To our knowledge, this disparity in results has not been 
studied further. At an ultrastructural level, NEP seems to be localized in the plasma 
membrane of axons, terminal boutons and possibly dendrites 145. Moreover, 
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immunostaining suggests that in the hippocampus, NEP colocalizes with markers for 
glutamatergic neurons, but not with cholinergic or catecholaminergic neurons 159. Since 
cholinergic neuronal loss is believed to be an early marker of AD, it is possible that the 
lack of NEP expression in cholinergic cells may contribute to an increased amyloid load 
and cell death of these cells.   
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Figure 2: Structure of NEP protein. NEP is shown with the short cytoplasmic and 
transmembrane (TM) domain. Also shown are the zinc-binding site (blue), glycosylation 
sites (red), sulfide-binding sites (black) as well as the sites involved in the formation of 
the active site (silver). The numbers indicate the amino acid number at that site of the 750 
AA protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
Role of the microtubule associated protein tau in AD 
 Post-mortem AD brains consistently showed one of the hallmarks associated with 
AD – neurofibrillary tangles, and it was eventually observed that these tangles were a 
consequence of a dysregulation of the well-controlled process of microtubule 
assembly/disassembly 160-162. The constituent of these filaments was found to be 
hyperphosphorylated tau protein 163. Soon after, a mechanism of characterizing disease 
progression was devised by Heiko Braak 164. In a seminal paper, Braak and Braak (1991) 
described worsening AD pathology and gave a quantitative description of stages 1-6 to a 
qualitatively determined increased amount of neurofibrillary tangles. This 
characterization is still used today to describe AD disease progression. 
  Microtubule associated protein tau (MAPT) is found on chromosome 17, 
comprises 16 exons and is 100kb in length 165. The tau gene has 4 domains – an acidic N-
terminal domain, a proline-rich domain, a tubulin-binding repeat domain and an acidic C-
terminal domain 166. In humans, the tau gene is alternatively spliced into 6 isoforms – due 
to a combinatorial splicing of one of exons 2, 3, 10 as well as its microtubule-binding 
domains 167. The longest isoform is 441 amino acids in length 166.  
 Under normal conditions, tau interacts with tubulin and promotes microtubule 
assembly and stability. When tau is phosphorylated, it promotes disassembly and 
therefore, the phosphorylation of tau is crucial to maintain integrity of the cell 168 . 
However, during diseased states such as AD, and other tauopathies such as Pick disease, 
dementia pugilistica, etc., tau is heavily phosphorylated and the homeostasis between 
phosphorylation and dephosphorylation is lost 168,169. In AD, all 6 tau isoforms are 
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hyperphosphorylated 170. In AD brains, tau protein is 3 to 4 fold hyperphosphorylated 
compared to age-matched non-AD brains 171. Therefore, reducing phosphorylated tau 
should be a suitable therapeutic target for AD. 
 Both in vivo and in vitro work affirm the neurotoxicity observed in response to 
experimental induction (or reduced neurotoxicity as a result of reduced) of 
hyperphosphorylation of tau 172-176. As a proof-of-concept, the administration of human 
tau oligomers into mice resulted in impairment of LTP as well as reduced memory 
formation 177. The measurement of phosphorylated tau and/or total tau in CSF has been 
studied as a possible biomarker for diagnosing AD onset/risk 178,179. Several groups are 
looking at the ratio of phosphorylated tau to Aβ42 in the CSF as a more accurate 
biomarker for diagnosing early stage AD 180-182.   
A review of AD treatment  
 In accordance with the prevalent in vitro and in vivo data, reduction of APP and 
BACE1 and/or an increase in NEP expression should result lowered Aβ levels and 
subsequently amyloid plaque. Congruently, a reduction in total tau and/or phosphorylated 
tau should result in a reduction in neurofibrillary tangle formation. Using these general 
hypotheses, many pre-clinical and clinical trials have been conducted to abrogate plaque 
and tangle formation and improve cognitive outcomes. Targeting either active (injection 
of Aβ antigen itself) or passive (injection of antibodies to Aβ) immunity, vaccines 
targeting monomeric or fibrillary forms of Aβ have gone to clinical trial 183,184.  
 CAD106 (Novartis) is an active vaccination against Aβ and successfully reduced 
plaque burden in transgenic mice 185 without the unwarranted T-cell responses seen with 
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earlier iterations of Aβ antibodies. CAD106 was well-tolerated in a vast majority of 
patients studied and has recently completed phase 2 clinical trials – although the results 
of their study are not yet available.  
 Targeting passive immunity, Solanezumab (Lilly) recently went to phase 3 trials. 
This antibody, which targeted monomeric Aβ, was well-tolerated but showed little 
cognitive improvement during the trial 186,187, although a sub-group of patients did show a 
reduction in cognitive decline. Bapineuzemab went through 2 clinical trials that showed 
no improvement in expected phenotypic outcomes, and consequently 2 other planned 
clinical trials with Bapineuzemab were terminated 188. Gantenerumab, an antibody 
against fibrillary form of Aβ, was well-tolerated and is currently in phase 3 trial – both as 
a stand-alone drug, as well as in combination with a BACE1 inhibitor 189-191. Finally, 
bimonthly subcutaneous injection of Crenezumab are being administered to AD patients 
with autosomal-dominant gene mutations; this study is in phase 2 and is scheduled to 
complete in 2020 192. 
 BACE1 inhibition is an obvious theoretical target for reducing Aβ, as it is the 
rate-limiting enzyme in Aβ generation. MK-8931 (Merck) is a well-tolerated 
uncompetitive antagonist in phase 3 trial (clinical trial identifier: NCT01739348), but was 
recently discontinued 193. Recently, a clinical trial with BACE1 inhibitor (LY-2886721) 
194 was terminated due to liver toxicity (but see 195). Inhibiting γ-secretase should also 
reduce Aβ levels and therefore semagecestat (Lilly) – a γ-secretase inhibitor – showed 
promising reduction of plasma Aβ levels in phase 1 and 2 clinical trials 196. However, 
phase 3 trials with semagecestat were abandoned as some patients showed worsening of 
cognitive function as well as an increase in skin cancer rates 197,198. 
17 
 To our knowledge, no clinical trials have been conducted with drugs increasing 
NEP expression/activity. Sacubitril (Novartis) is a NEP inhibitor that has been 
extensively studied as a means to control hypertension 199 (and see clinical trial identifier: 
NCT01692301). The ability of sacubitril to cross the blood-brain barrier (BBB), or its 
possible effect on Aβ levels and cognition, remains unexplored. While inhibiting NEP 
would not be desirable, it is worth exploring the effect of the same on brain Aβ levels, as 
it would elucidate whether NEP activity in the brain regulates levels of Aβ in vivo. There 
is currently one tau vaccine – AADvac1 – which showed preclinical promise in reducing 
tauopathies in rats 200. 
 It is important to note that the few drugs approved for AD therapy are not targeted 
at Aβ generation, clearance or tau at all. Cholinesterase inhibitors, such as donepezil, 
galantamine, and rivastigmine have success in retarding AD development, especially 
when administered early 201. Unfortunately, there is great heterogeneity in the efficacy of 
these drugs as well 201, for example, galantamine was shown to modulate nicotinic 
receptors as well 202. Memantine, an NMDA partial antagonist, is approved for moderate 
to severe AD treatment. This drug has previously shown benefit in cognitive outcomes, 
however, a recent study showed that memantine did not improve cognitive outcomes in 
mild to moderate AD 201,203.   
 Therefore, due to the limited success of AD therapies, a novel means to reduce Aβ 
levels is warranted. 
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MicroRNA 
Overview 
 MicroRNA (miRNA) were initially discovered in C. elegans in the early 90’s 204. 
It was shown that LIN-14, a factor important to larval development was regulated by lin-
4, which happened to be a 22 nt non-coding RNA. Additionally, it was observed that lin-
4 was partially complementary to a sequence on the LIN-14 3’ UTR 204. Therefore, the 
idea that short non-coding RNA could influence protein expression by targeting the 
3’UTR was generated. In 2000, in another seminal paper, let-7 was discovered 205 as a 
regulatory miRNA controlling processes involved in larval development and maturity. 
Since then, a multitude of discoveries of miRNA across various species has been made. 
Current estimates are approximately 30,000 mature miRNA across 206 species 206. While 
estimated to be ~2400 in number, recent work has revealed the presence of 3707 novel 
miRNA in the human genome 207. 
Nomenclature and biogenesis of miRNA 
 The nomenclature of miRNA can occasionally be confounding, but follows 
consistent principles. The first three letters indicate the species to which the particular 
miRNA is endogenous to – for example, hsa- and mmu- indicate human and mouse 
miRNA respectively. The miRNA numbers reflect the order in which they were 
discovered. For example, miR-20 was discovered before miR-298. If the mature sequence 
of two miRNA is very similar, they are often given the same number followed by a letter. 
For example, miR-20a and miR-20b are two miRNA that have similar mature sequences 
in their seed sequence, yet are derived from two different chromosomes. Occasionally, a 
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few miRNA are generated from close proximity within the same genomic region – such 
as the miR106a-363 family. This family comprises of miR-106a, miR-18b, miR-19b-2, 
miR-92a and miR-20b and miR-363, and are all derived from a ~1kb region on 
chromosome X 208.  
 The biogenesis of miRNA is a well-regulated and well-conserved process 
involving a variety of proteins and chaperones (For review, see 209). MiRNA are 
transcribed by RNA Polymerase II as primary miRNA comprising a stem loop structure 
as well as the double-stranded RNA containing the mature miRNA sequence as well as a 
poly-A tail and a 5’ overhang. These miRNA can have their own promoter elements and 
can often reside in intronic regions on the genome. For example, miR-298 and miR-20b 
reside in intronic regions on chromosome 20 and chromosome X, respectively. The 
primary miRNA is then acted upon by Drosha and DiGeorge syndrome critical region 8 
(DGCR8) which generates the double-stranded stem-loop structure called the pre-
miRNA. The pre-miRNA is then exported out of the nucleus to the cytosol by exportin-5. 
In the cytosol, Dicer and TAR RNA-binding protein (TRBP) act synergistically to excise 
out the stem-loop, generating the double-stranded RNA. The double-stranded miRNA is 
then loaded onto argonaute (AGO)-2 protein. Work by Schwarz (2003) explained an 
initially confounding question – which of the two strands becomes the mature, functional 
RNA. Schwarz and colleagues suggest that the strand with the less thermodynamically 
stable 5’ end will become the mature strand, and that a single hydrogen bond can be the 
deciding factor discerning which of the two strands becomes the mature strand 210; the 
argonaute-miRNA forming the RNA-induced silencing complex (RISC). This RISC then 
targets mRNA targets based on the sequence of the mature strand. It should be noted that 
20 
RISC-independent miRNA activity – based on secondary structure alone – has been 
reported 211.  
 In canonical miRNA binding, the mature miRNA targets a 7-8 nt complementary 
sequence usually on the 3’UTR mRNA, usually this involves a “seed” sequence 
beginning 2-6 nt from the 5’ end of the miRNA 212. However, non-canonical binding 
involving imperfect complementarity in the seed sequence and nucleation due to 
mismatched pairs have also been reported 213. After the target has been loaded onto RISC, 
either the mRNA transcript is destabilized or translation is inhibited, subsequently 
affecting protein expression 214.  
MiRNA in disease states and AD 
 As more miRNAs have been discovered, it has become apparent that they play a 
multitude of roles, and the perturbation of these miRNA can lead to disease states. In the 
early 2000s, a role for miRNA in human cancer was discovered 215. MiR-15a and miR-16 
were found to be important to processes in chronic lymphocytic leukemia 215,216. Roles 
for miRNA in the onset of pancreatic cancer and lymphoma were soon elucidated as well 
217,218. While the miRNA involvement in cancer was gathering storm, it was also 
becoming apparent that miRNA could regulate other disease states as well. Huang et al. 
(2007) showed that miR-125, miR-223 and miR-382 can inhibit HIV replication 219. In 
the CNS, miR-34a, miR-155 and miR-326 levels were found to be increased in multiple 
sclerosis (MS) and were found to be negative regulators of CD47, which lead to 
increased macrophage-mediated phagocytosis of myelin 220 
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 The involvement of miRNA in AD was first reported in the mid-2000s. Various 
miRNA have been found to be upregulated or downregulated in brain tissue derived from 
AD patients when compared to that derived from control patients. For example, miR-34 
was found to be upregulated in the hippocampus 221, while miR-146a was found to be 
upregulated in the temporal cortex as well as in the hippocampus 222. Meanwhile, miR-
107, miR-181 and miR-106 were all found to be downregulated in the temporal cortex 
derived from AD patients 223-225, whereas miR-29 was found to be downregulated in both 
temporal cortex as well as the cerebellum of AD patients 226. MiRNA can also be 
successfully detected and differentially expressed in biofluids such as urine, CSF and 
serum 224,226-230 thereby implicating their utility as possible biomarkers for diagnosing AD 
in a noninvasive manner. 
 A number of laboratories have identified miRNA that modulate the expression of 
proteins implicated in the pathogenesis of AD, such as APP, BACE1, NEP and MAPT. 
For example, Niwa et al (2008) showed that in C. elegans, APP-like-1 (apl-1) protein is 
regulated by the let-7 family of miRNA 231. Since then, miR-101 232,233, miR-16 234,235, 
miR-153 236,237, miR-384 238, miR-193b 239 and miR-200b 240 have been found to regulate 
the expression of APP in vitro. Moreover, a number of SNPs were found on the APP 
3’UTR in AD patients, suggesting further possible targets for miRNA 241. 
 Only few miRNA study involves NEP Thompson and colleagues (2011) showed 
that miR-155 indirectly regulates the expression of NEP – by targeting the PU.1 
transcription factor 242. Therefore, the possible regulation of NEP by miRNA remains 
largely unexplored. 
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 Many groups have also shown repression of BACE1 expression by a variety of 
miRNA. These include miR-29a/b and miR-9 226, miR-195 243, miR-339-5p 88, miR-384 
238, miR-135a 240 and miR-135b 244. In rodent models, miR-124, miR-298 and miR-328 
were also shown to regulate BACE1 expression 245,246 .  
 Emerging work in the last few years has begun to elucidate the regulation of total 
tau expression as well as phosphorylated tau by miRNA. The first indication of this was 
the observation that Dicer knock out mice showed an increased expression of tau protein 
247. Given the role Dicer plays in miRNA processing, it was hypothesized that tau is 
under the regulatory control of unidentified miRNA. Notably, miR-16 and miR-132 are 
involved in the regulation of splicing exon 10 of tau as well as the phosphorylation of tau 
247,248. Work in a gut cell lines revealed that miR-34c-5p regulates tau protein as well 249. 
Separate groups identified miR-138, miR- 125b, miR-922 and miR-125b regulating the 
phosphorylation of tau indirectly 250. MiR-138 was shown to increase tau phosphorylation 
by targeting the 3’UTR of the Retinoic acid receptor alpha (RARA) 250. RARA, in turn, 
increased the activity of glycogen synthase kinase 3β (GSK3β) – capable of 
phosphorylating tau.  Similarly, Zhao et al (2014) showed that miR-922 promotes tau 
phosphorylation by targeting the 3’UTR of ubiquitin carboxy-terminal hydrolase L1 
(UCHL1). The reduction in UCHL1 then contributed to increased phosphorylation of tau 
as well as tangle formation 251,252. MiR-125b was shown to increase tau phosphorylation 
by simultaneously increasing kinase and inhibiting phosphate expression 253. Finally, 
recent work showed miR-219 levels were reduced in AD autopsy brains and miR-219 
was shown to regulate total tau expression by binding directly to the tau 3’UTR 254.  A 
Table of miRNA regulating tau would be useful  
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 Free-floating, unbound miRNA are degraded by a variety of exonucleases, but 3’ 
methylation and sequestration by exosomes helps maintain miRNA integrity from 
exonucleases 255-257. In fact, emerging literature posits exosomes as an important means 
of miRNA transport between cells and in biofluids 258. Exosomes were discovered in the 
1980s and are nanovesicles (~30-100nm in size) that are capable of shuttling proteins, 
lipids and miRNA 258-260. Exosomes are released from a variety of cell types, including 
neurons, by budding from the plasma membrane 261,262. Various groups have successfully 
detected exosomes in biofluids such as blood, urine and CSF 263-265. While the isolation of 
exosomes can be tricky 258,266, several groups have profiled miRNA signatures from 
exosomes as a means to identifying miRNA differentially expressed in AD 265,267-269. Gui 
et al. (2015) showed that exosome-derived long non-coding RNA can be differentially 
expressed in patients with AD 265. Similarly, in a small cohort of AD and control patients, 
CSF-exosomal profiling identified 75 miRNA upregulated miRNA and 74 downregulated 
miRNA 269. Of these, miR-146a, miR-11 and miR-1274 were identified as strongest 
candidates after statistical correction 269. The Exocarta website (www.exocarta.org) 
identified ~2400 exosomal miRNA across various multiple organs; therefore, it is likely 
that many more candidates will be identified, as the field matures. Finally, using deep-
sequencing, miRNA from exosomes were also successfully detected from CSF-derived 
exosomes 268.  
Environment, epigenetics and miRNA 
 In accordance with models posed elsewhere 270, Alzheimer’s disease onset may be 
a consequence of the complex interplay of genetics, environment and epigenetics 271. In 
order to show a role for miRNA in this model, one to show that miRNA can modulate 
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epigenetic factors, and itself be modulated by environmental factors. The modulation of 
various epigenetic markers has been shown in Arabidopsis 272, mouse models 273 and 
human clinical samples 274. Further, miRNA-mediated methylation 272,275-277, acetylation 
273 and ribosylation 278 have been reported; primarily related to tumorigenesis. 
Interestingly, miRNA themselves can be under the influence of epigenetic modification 
of their gene promoters 279-281. Therefore, there seems to be a complex, bidirectional 
interplay between miRNA and epigenetic modification 282. Moreover, it has been shown 
that environmental factors such as cigarette smoke   283, physical activity 284, metal 
exposure 285 and infection 286 can regulate miRNA levels.  
Predicting miRNA binding 
 There are many commonly used bioinformatics tools to identify putative miRNA 
binding sites within the 3’UTR mRNAs that target expression of proteins in AD. 
TargetScan searches perfect complementarity in the seed region of the miRNA and then 
filters out complementarity outside the seed sequence 287. TargetScan also favors well-
conserved putative binding sites on UTRs 287. The MiRanda algorithm favors binding at 
the 5’ end more than at the 3’ end, and then also ranks predictors based on the free energy 
calculation of binding 288. The PicTar algorithm relies on conservation of the 3’UTR and 
the thermodynamic stability of binding, and is therefore less biased by the seed sequence 
289. Similarly, DIANA-MICROT looks beyond the 3’UTR – to the coding region and 
only considers the free energy of binding sites 290. The PITA algorithm is unique that it 
considers the secondary structure of the transcript along with the complementarity in the 
seed sequence 291. Finally, RNA-hybrid looks only at binding efficiency, not conservation 
or canonical seed-sequence binding 292.  
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MiRNA in clinical trials 
While delivering miRNA to the brain is problematic, microRNA and their 
inhibitors are now being used in clinical trials. An University of Iowa trial (Clinical trial 
#NCT02579187) will evaluate the effect of miRNA delivery on bone development and 
inflammatory markers after oral surgery. An earlier clinical trial attempting intravenous 
liposomal injection of miR-34 to treat liver cancer (Clinical trial #NCT01829971) or 
melanoma (Clinical trial #BCT02862145) were terminated due to immune-related side 
effects. Meanwhile, multiple clinical trials (NCT01612871, NCT02009852, 
NCT01207531, NCT02247453, NCT03059524, NCT02466113, etc) are examining the 
diagnostic potential for miRNA in various human disease states. In Alzheimer’s disease, 
a recently completed trial (NCT02129452) measured miR-206 from the olfactory 
neuroepithelia of AD patients. The results of this study are not available. Similarly, the 
levels of miR-107 as a function of gemfibrozil intake in AD patients (NCT02045056) or 
as a clinical diagnosis of BACE1 expression in the CSF (NCT01819545) are ongoing. 
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Chapter 2: Overall Rationale 
 AD is a complex disorder involving multiple proteins with their own respective 
regulatory mechanisms. Non-coding miRNA species are an important subsystem of this 
larger regulation of proteins. Therefore, identifying miRNA that regulate the proteins 
involved in AD would further elucidate the mechanism of the disease as well its 
progression. Given the importance of APP, BACE1 and NEP to the amyloid hypothesis, 
we focused on identifying miRNAs which target these proteins and confirming that 
specific interaction via well-designed experiments using human epithelial, neuronal and 
glial cell lines, as well as human primary mixed brain cultures. Notably, use of well-
characterized autopsied human brain tissue specimens from control and Ad subjects is 
another major strength of the work presented herein. In addition to understand the 
biochemical cascade of the disease, we believe that miRNA may be used as novel, 
clinically relevant therapeutic agents in the treatment of AD. Finally, the identification of 
SNPs within proximity to the genomic regions of these miRNAs may further confirm the 
importance of these miRNA to disease state and/or highlight genomic signatures of the 
disease itself. Our overall experimental workflow is shown in Figure 3. 
 We hypothesized that identified miRNA would each reduce respective targets, 
APP, BACE1 and NEP respectively and subsequently alter levels of soluble Aβ. 
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Chapter 3: Specific Aims 
 Our overall aim was to functionally validate miRNA that target proteins 
implicated in the generation and clearance of beta-amyloid. Understanding novel 
function(s) of the proposed miRNAs, such as miR-20b and miR-298, is important 
irrespective of their role in the “amyloid hypothesis”. In particular, we were interested in 
identifying miRNA that may target both APP, BACE1 and NEP and subsequently 
modulate levels of soluble beta-amyloid. Having identified miR-20b as a putative 
modulator of APP, and miR-298 as a putative modulator of both APP and BACE1, our 
specific aims were – 
Specific Aim 1: To show that miR-20b modulates endogenous APP levels and 
subsequently levels of beta-amyloid. 
-SA 1a: To show that miR-20b targets the APP mRNA 3’UTR and modulates 
endogenous APP levels in different mammalian cells and human primary mixed brain 
cultures. 
-SA 1b: To show that miR-20b modulates levels of soluble Aβ. 
Specific Aim 2: To show that miR-298 modulates both endogenous APP and BACE1 
levels and subsequently levels of beta-amyloid. 
-SA 2a: To show that miR-298 targets both the APP mRNA and BACE1 mRNA 3’UTRs 
and modulates expression of both proteins in different mammalian cells and human 
primary mixed brain cultures. 
-SA 2b: To show that miR-298 modulates levels of soluble Aβ. 
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Specific Aim 3: To study levels of NEP protein in various cell types and tissues and 
identify putative miRNA that target NEP mRNA 3’UTR. 
-SA 3a: To successfully detect NEP protein in mammalian cell cultures and human fetal 
brain, lungs and kidney tissues. 
-SA 3b: To identify putative miRNA that target the NEP mRNA 3’UTR. 
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Figure 3: Workflow diagram showing steps involved in identifying miRNA 
implicated in the modulation of proteins implicated in AD. This methodology was 
followed for the work herein and starts from bioinformatics tools, through validation of 
miRNA and subsequent identification of SNPs in proximity to the miRNA gene. 
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Chapter 4: Materials and Methods 
Cell Culture 
All cell lines were procured from ATCC, except LNCaP cells, which were a 
generous gift from Dr. Kavita Shah (Purdue University). Cervical cancer cell (HeLa), 
human glioblastoma-astrocytoma (U373) and neuroblastoma (NB) (SK-N-SH) cells were 
grown in Minimum Essential Medium (MEM, Life Tech) enriched with 10% fetal bovine 
serum (FBS, Roche) and 1x antibiotic-antimycotic. Human prostate cancer cells (LNCaP) 
were grown in Roswell Park Memorial Institute (RPMI) media enriched with 10% FBS 
and 1x antibiotic-antimycotic. Rat pheochromocytoma cells (PC12) were grown on 
collagen (Roche)-coated plates and were cultured in RPMI with 10% horse serum (HS), 
5% FBS and 1x antibiotic-antimycotic. In order to differentiate NB and PC12 cells, the 
media was switched to low serum (1%) and were treated with 10µM all-trans retinoic 
acid (ATRA, Roche) or 50ng/ml nerve growth factor (NGF, Sigma) for 7-10 days. All 
cells were grown in 100mm dishes until 70% confluent and either lysed (as described 
below) or split into the appropriate format (Table 1). All cell lines were grown in a 5% 
CO2 incubator. 
Human fetal brain culture 
Human fetal brain (HFB) culture was grown as described previously 293. Briefly, 
tissue was received in Dissection media (Hibernate-E (Gibco)) media enriched with 1x 
Glutamax (Gibco), 1x Antibiotic-antimycotic, Normocin and B27 (Gibco)) and the blood 
vessels were removed. The tissue was then sliced into small sections using a sterile 
scalpel, and placed into 5mL of Trypsin-EDTA and placed on a shaker for 10-15 minutes. 
The trypsin was then inactivated using 1mL of HS and the suspension is centrifuged to 
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remove the trypsin. The pellet was resuspended in 5 ml of fresh dissection media, and 
then using a wide-bore Pasteur pipette, the tissue is triturated further. This step was 
repeated one more time. The viability of the cells was determined using the trypan-blue 
exclusion method 294 and the cells were plated at the appropriate density, in accordance 
with the format of the experiment (Table 1). After counting and plating, the cells were 
placed in a 37 °C with 5% CO2 and 9% O2. 
Plating of cells  
To count the cells, the 100mm plate was washed once with sterile phosphate-
buffered saline (PBS) and 3 mL of Trypsin-EDTA was applied to the cells to dislodge 
them from the plate. 10mL of serum-containing media was added to inactivate the 
trypsin, followed by centrifugation and removal of the trypsin-containing media. The cell 
pellet was resuspended in fresh media and 30µL of the suspension was dissolved in 
trypan blue and mounted onto a hemocytometer. In accordance to the count obtained, 
cells were seeded onto 24-well, 48-well or 96-well (Table 1). 
Preparation of “cell lysate” and protein estimation 
Cell culture media was removed and stored at -80°C. The adherent cells were 
washed with cold PBS. After removal of PBS, appropriate amount of mammalian protein 
extraction reagent (M-PER, ThermoFisher) was added to lyse the cells (Table 1). The 
plate was then placed on a shaker at 4°C for 10 minutes, after which the lysate was 
collected into an autoclaved 1.5 mL tube (Eppendorf) and centrifuged. The supernatant 
was stored and used for western blotting and enzyme linked immunosorbent assay 
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(ELISA) as described below. For 96-well plates, lysates were transferred to opaque-
bottom plates for CTG/luciferase assay (see below). 
 
Format Number of cells per well Amount of M-Per 
buffer used to lyse 
96-well 75,000 50uL 
24-well 150,000 100-120uL 
6-well 500,000 300uL 
Table 1: Various cell-culture formats used for the in vitro study of miRNA effects on 
AD-implicated proteins. 
 
 
 
 
 
 
 
 
33 
Target Source/Vendor Clone # Catalog # Host Dilution 
Which 
buffer? 
Alpha-tubulin Sigma  T9026 Mouse 1:1,000,000 
APP Millipore 22C11 MAB348 Mouse 1:1000 
BACE1 Cell signaling D10E5 5606 Rabbit 1:1000 
BACE1 Abcam  Ab2077 Rabbit 1:1000 
Beta-Actin Sigma  A5441 Mouse 1:1,000,000 
Neprilysin Abcam  Ab951 Mouse 1:1000 
Neprilysin Fabgennix 101AP 101AP Rabbit 1:150 
Neprilysin Fabgennix 112AP 112AP Rabbit 1:150 
Neprilysin Fabgennix 131AP 131AP Rabbit 1:150 
Neprilysin Fabgennix 141AP 141AP Rabbit 1:150 
Neprilysin Fabgennix 151AP 151AP Rabbit 1:150 
Neprilysin Fabgennix 161AP 161AP Rabbit 1:150 
Neprilysin GeneTex  GTX53381 Rat 1:500 
Neprilysin GeneTex  GTX111680 Rabbit 1:1000 
Neprilysin Millipore  AB5458 Rabbit 1:1000 
Neprilysin RnD  MAB1126 Rat 1:500 
Neprilysin RnD  AF1182 Goat 1:500 
Neprilysin Santa Cruz  SC-46656 Mouse 1:1000 
Tau Abcam  Ab80579 Mouse 1:1000 
Table 2: List of antibodies used for western blotting and immunocytochemistry. 
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Secondary 
antibody 
Company Catalog # Dilution 
Goat anti-mouse Rockland 610-1319 1:3000 
Goat anti-rabbit Rockland 611-1322 1:3000 
Donkey anti-goat Jackson 705-035-003 1:3000 
Goat anti-rat Rockland 212-1302 1:3000 
Table 3: List of horseradish peroxidase-conjugated secondary antibodies used for 
western blotting. 
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DNA transfection 
 Using the NanoDrop spectrophotometer, the concentration of the appropriate 
DNA plasmid (Table 4) was measured. The previous day, approximately ~75,000 
cells/well were seeded onto a 96-well plate. On the day of the transfection, 300ng/well of 
DNA and 0.3ul/well of Transfectin (BioRad) reagent were suspended in 20µl/well Opti-
MEM (Gibco) media, mixed and incubated at room temperature for 20 minutes. 80uL of 
fresh media devoid of antibiotics as well as the transfection complex was added to each 
well and left undisturbed in a 5% CO2 incubator for 48 hours. For miRNA reporter 
assays, the same procedure was used, except 50nM of miRNA mimic was added to the 
DNA-transfectin-Opti-MEM complex. 
MiRNA transfection 
 5 nmol of mature miRNA or siRNA mimic (ThermoFisher) was resuspended in 
1000µL of nuclease-free water to obtain a final concentration of 5uM. Transfections were 
performed one day post-seeding, in the case of HeLa and U373, and at DIV 17 of the 
HFN culture. Lipofectamine RNAiMax was used as a transfection reagent and all 
miRNA-RNAiMax complexes were suspended in Opti-MEM media and brought up to a 
volume of 100uL. For cell line experiments, 20nM of siRNA, 50nM of miRNA and 
2ul/well of RNAiMax were used, whereas, For HFN transfections, 50nM of siRNA, 
75nM of miRNA and 3ul/well of RNAiMax were used. Plates were left undisturbed in 
the incubator until time of harvest – 72 hours later. For the time course experiment, wells 
were lysed at intervals of 24 hours. 
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Plasmid name Company/modification Plasmid size (kb) 
PsiCheck2 Promega/none 6.3 
APP 3’ UTR Promega/APP 3’UTR insert (1.2 kb) 7.5 
MiR-298 mutant-1 Promega/APP 3’UTR with miR-298 site-1 
mutagenized  
7.5 
MiR-298 mutant-2 Promega/APP 3’UTR with miR-298 site-2 
mutagenized 
7.5 
MiR-20b mutant Promega/APP 3’UTR with 20b site 
mutagenized 
7.5 
NEP 3’UTR Promega/NEP 3’UTR insert (3.3 kb) 9.5 
BACE1 3’UTR Promega/BACE1 3’UTR insert (3.9 kb) 10.2 
Table 4: List of DNA plasmids used.  
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Western blotting 
 In accordance with our data showing linearity for well-expressed proteins such as 
APP and BACE1 (See Figure 4), between 3ug-9ug of protein was loaded onto each well 
per gel, whereas for lowly expressed NEP, between 10-150ug of protein was loaded and 
run on either 10-lane, 15-lane or 26-lane pre-cast gels (BioRad). The gels were run for 1 
hour at 200V and transferred onto PVDF-membrane using the iBlot system (Invitrogen). 
After transferring proteins, membranes were briefly immersed in methanol, acetic acid 
and then stained with Ponceau S (Sigma). After confirmation of transfer via Ponceau-S 
stain, membrane was blocked for 1 hour in 5% milk in Tris-buffer saline with Tween-20 
(TBST).  
 After blocking, the blots were probed with the appropriate primary antibody (see 
Table 2 and Figure 2) for either 3 hours at room temperature or overnight at 4°C. The 
membrane was subsequently washed in TBS (3x 5 min each) and then probed with the 
appropriate horseradish peroxidase (HRP) conjugated-secondary antibody (see Table 3) 
for 1 hour, followed by washing in TBST. Finally, the bands were visualized using the 
enhanced chemiluminescence (ECL) method. Antibodies used in the work herein were 
studied for linearity of their western blot signal (Figure 4). 
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Figure 4: Linearity of protein detection in Western blot. Lanes loaded with pooled 
sample of autopsied AD brain tissue extracts with 3ug, 6ug and 9ug of protein and probed 
with 4 key antibodies used in this work. Non-normalized densitometry is also shown to 
confirm linearity of detection. 
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Immunocytochemistry (ICC) 
 Human neuronally differentiated (NB+RA) cells were grown as previously 
described (see Methods). Cells were fixed using 4% paraformaldehyde and permeabilized 
using 0.1% Triton-x 100. Wells were blocked for 20 minutes with 10% HS in phosphate-
buffered saline (PBS). Primary antibody (1:100, Figure 2) was dissolved in 1% HS and 
applied to the wells and left overnight at 4°C. After rinsing 3 times with PBS, cy3-
conjugated goat anti-rabbit antibody was applied to the cells for 1 hour and kept in the 
dark to avoid bleaching of the fluorophore. The wells were visualized using a fluorescent 
microscope (Leica) using the red-filter. For a control, one well was treated with 1% HS in 
PBS, devoid of primary antibody, followed by secondary antibody application. This well 
served to visualize the immunoreactivity of the secondary antibody itself. 
ELISA of different proteins and peptides 
 Two independent, specific and sandwich ELISA protocols were used to measure 
levels of different Aβ peptides as briefly described below. For the Aβ (1-40) and Aβ (1-
42) ELISA, the conditioned medium (CM) samples were used to measure levels of 
soluble Aβ peptides as per the manufacturer’s protocols (IBL America). Briefly, 5 µL 
(for Aβ 40) or 25µL of CM (for Aβ 42) was brought up to 100µL with EIA buffer and 
applied to wells pre-coated with a monoclonal antibody targeting the specific Aβ peptide 
overnight. The following day, HRP-conjugated polyclonal detection antibody was 
applied after washing, and TMB-substrate was used to measure optical density (OD) at 
450nm. The actual Aβ peptide content was calculated by comparing ODs against those 
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generated by a standard curve generated using known amounts of recombinant Aβ 
peptides (See Figure 6 for examples of standard curves).  
 NEP ELISA (RnD) procedure was performed in accordance with the protocol 
with the following modification. Briefly, plates were coated with a capture antibody 
targeting NEP. After a blocking step, sequential addition of lysate, detection antibody and 
HRP-conjugated to biotin-streptavidin steps for visualization were performed. Based on 
experience with previous ELISAs, we observed that the OD) measurements in ELISA 
were a consequence of cross-reactivity of the amplification step. To eliminate the 
possibility of a non-specific result, we tested each sample both with and without the 
addition of the detection antibody. The ODs were then calculated as OD with detection antibody 
– OD without detection antibody. The resultant OD values were normalized to the mean of the 
control values and exhibited as shown. 
NEP enzyme assay 
Commercially available NEP substrate (RnD), which is tagged to a fluorophore 
(mca) and a quencher (dnp), was added onto each well of a 96-well plate in assay buffer 
(100mM Tris-HCL pH 7.5, 50mM NaCl, and 10 µM ZnCl2). Both the NEP inhibitor 
(Thiorphan, 10µM) and ACE inhibitor (Captopril, 0.1µM) were added to appropriate 
wells. Recombinant NEP (RnD) was serially diluted to generate a standard curve to 
normalize unknown samples. All volumes were brought up to 100µl of assay buffer and 
placed at 37 C for 1 hour in the dark. Readings were taken for 90 minutes, every 2 
minutes with excitation at 320nm and emission at 405 nm. 
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Figure 5: The immunogens used to generate various commercially available 
antibodies. The information provided by various vendors regarding the immunogens for 
their respective antibodies is indicated here. As shown above, the regions targeted by 
various antibodies are short (FabGennix) to medium length (Santa Cruz) to full length 
(Millipore). Additionally, regions involved in various domains are also covered by the 
multitude of immunogens. FabGennix 151AP was generated by injecting three epitopes – 
FabGennix 101AP, 112AP and 131AP, and is therefore not shown on this diagram. 
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Figure 6: Standard curves generated for IBL Aβ (1-40) and Aβ (1-42) ELISAs. 
Known quantity of each peptide was serially diluted as per the manufacturer’s 
instructions. Each color represents standard curve generated in a separate ELISA 
experiment to ensure consistency of each ELISA protocol. 
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Site-directed mutagenesis 
 The target sites of miR-298 and miR-20b on the APP 3’UTR were identified 
using Targetscan. The two sites were mutated independently using the QuikChange 
Lightning kit (Agilent). Briefly, primers generated with regions overlapping the 7 
nucleotide target sites were used in the mutagenesis step. The previously mentioned APP 
mRNA 3’UTR was denatured and the mutagenic primers were extended with the 
PfuTurbo DNA Polymerase enzyme provided by the kit. Parental DNA was digested by 
Dpn I restriction enzyme, and transformation into competent cells was completed with 
the digest. To confirm mutagenesis, plasmids were run on a DNA gel, showing the 
introduction of a novel enzyme site – replacing the miR-298 target site. 
Luciferase assay 
 30µL of lysates were transferred to an opaque-bottom 96-well plate. Protocol was 
run on a GloMax system according to the manufacturer’s instructions. First, 30uL of 
substrate for firefly luciferase activity was added to each well, and luciferase activity was 
recorded. After a quenching step, substrate for Renilla luciferase was added to each well 
and luciferase activity was recorded. The ratio of Renilla/firefly luciferase was calculated 
and plotted. 
Cell-titer Glo (CTG) assay 
 30uL of lysates were added to an opaque-bottom 96-well plate. To each well, 
30uL of CTG buffer (Promega) was added, and the subsequent ATP-dependent release of 
light was measured and plotted. 
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Rat tissue processing 
 Two female 74 day old Wistar rats were humanely sacrificed by decapitation and 
their liver, lung, kidney, cortex and hippocampus were removed and placed in ice-cold 
PBS as per the IACUC protocol. These tissues were homogenized in Polytron and 
centrifuged at approx. 10,000g for 10 minutes, and their supernatant was stored and used 
in subsequent western blotting and ELISA experiments. 
Fetal tissue processing 
 Fetal brain, kidney, spleen/pancreas, heart, lung and adrenal cortex were received 
in Hibernate-E media. Each tissue was rinsed with PBS and the blood vessels were 
removed using forceps. The tissue was suspended in 300µL of M-Per buffer and 
dissociated in the polytron until a homogenous suspension was visible. These samples 
were centrifuged at ~10,000 g for 10 minutes and the supernatants were used for western 
blotting and ELISA experiments. 
Reverse transcription quantitative PCR (RT-qPCR) 
 Post-mortem tissues were homogenized and RNA extracted as previously 
described 236. RNA was first converted to cDNA using the Taqman miRNA RT kit (Life 
Sciences). The assay was run in accordance with the manufacturer’s protocol. Briefly, 
RNA, oligoprimers, dNTPs and reverse transcriptase were brought up to a volume of 
20uL per reaction and incubated on a thermocycler. The settings used were: 16°C for 30 
minutes, 42°C for 30 minutes and 85°C for 5 minutes. The cDNA was then combined 
with the universal PCR master mix and the fluorescent-probe-containing miRNA assay 
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(specific for either miR-298 or miR-20b) and analyzed on a 7300 RT-PCR instrument 
(Applied Biosystems). 
 Samples were quantified by comparison to a pre-generated standard of known 
amounts of RNA, which comprised a HPLC-purified synthetic miR-298 or miR-20b 
(Sigma) reconstituted to a stock of 10uM and serially diluted. 
Imaging and neurite measures 
Transfected plates were placed in the Incucyte Zoom (Essen Bioscience) and 
imaged once a day to obtain 4 time points: 24, 48, 72 and 96 hours. In a separate 
experiment, APP siRNA harvested plate was imaged at 72 hour only. Using the 
‘neurotrack’ analyzer, masking of cells and neurites were performed to ensure inclusion 
of cell bodies and neurites. Specifically, minimum cell body clusters were set to 50 µm2, 
Segmentation adjustment was set to 1.2, minimum cell width to 5µm, neurite filtering to 
‘best’, neurite sensitivity to 0.35 and the neurite width was set to 1 µm. Importantly, the 
same parameters were used for all the conditions analyzed. The neurite lengths and 
branch points obtained were normalized to the cell body clusters (a measure of cell 
number within a field of view). 
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Chapter 5: Specific Aim 1 – To show that miR-20b modulates endogenous APP 
levels and subsequently levels of beta-amyloid 
Rationale 
 The amyloid hypothesis implicates that APP plays a central role in the generation 
of potentially toxic amyloid-beta peptides. Therefore, understanding regulatory 
mechanisms governing the expression of APP would identify the biochemical cascade of 
pathway of AD leading to potentially novel AD drug targets. APP has previously been 
shown to be modulated by miRNA expression, such as miR-101 and miR-153 233,236 (. 
Our goal was to identify a miRNA that modulates APP as well as regulates levels of 
soluble Aβ peptide. Finally, having identified a miRNA which modifies this AD-related 
proteins/peptides, we were interested in the possible regulation of the genomic region of 
the miRNA itself. 
 Based on the bioinformatic prediction tools, we hypothesized that miR-20b would 
target the APP mRNA 3’UTR and reduce levels of both APP protein as well as soluble 
Aβ peptide. 
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Results 
MiR-20b targets the APPmRNA 3’UTR and is a negative regulator of APP 
expression 
Using at least 3 different predictive algorithms, we found that miR-20b was 
predicted to target the APP mRNA 3’UTR (Table 5). The TargetScan context ++ score of 
76 suggests that 76% of sites for this miRNA have less favorable scores than this site. 
The PhastCon score suggests that the target site for miR-20b on the APP mRNA 3’UTR 
is well conserved. The highly negative ΔΔG score from PITA suggests that the miRNA 
has high predicted binding affinity at that site. The predicted 7-mer-m8 target site on the 
APP mRNA 3’UTR is located at the 710-716 positions on the UTR (Figure 7). There is 
perfect complementarity between the seed sequence of mature miR-20b and this 7-mer 
target mRNA sequence, underlying the highly negative ΔΔG score. No sites were 
predicted for miR-20b binding in the coding region or the short of APP mRNA 5’ UTR. 
Confirmation of the miR-20b target site on the APP 3’UTR. 
Dr. Justin Long from our lab successfully inserted the full-length APP 3’UTR into 
a dual-luciferase reporter vector 233, thereby allowing us to test whether miR-20b targets 
the APP3’UTR. Using a lipid-based transfection system, we co-transfected HeLa cells 
with the luciferase reporter with three different miRNAs: miR-20b, miR-101 (positive 
control) and a negative control miRNA (NCM), which is not predicted to target the APP 
mRNA 3’UTR. We found that that the co-transfection of the reporter vector with miR-
101 and miR-20b reduced luciferase-mediated activity by 40% and 30% respectively 
(Figure 8A). Co-transfection with the negative control mimic had no effect on luciferase 
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activity. Together these results suggest that miR-20b targets the APP mRNA 3’UTR 
(Figure 8A). 
To confirm the validity of the predicted target site, we mutated the 7 nucleotide 
target site of miR-20b using the site-directed mutagenesis protocol (Figure 8B and 8C). 
We validated the mutagenesis by DNA restriction digestion (data not shown). Co-
transfection of the mutagenized APP 3’UTR with miR-20b revealed no reduction of 
luciferase activity (Figure 8C). In the same plate, wild-type APPmRNA 3’UTR co-
transfected with miR-20b showed a reduction of luciferase as previously shown (Figure 
8B). Together, these results confirm that the miR-20b targets specific sequences on the 
APP 3’UTR, which is the 710-716 site, as predicted. 
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Table 5 – Identification of miR-20b as a putative modulator of APP. Six separate 
bioinformatics algorithms predict that miR-20b targets the APP mRNA 3’UTR. An 
explanation for each score is also included herein. Crucially, each miRNA predictive tool 
has its own specific parameters for predicting putative miRNA. Some of these parameters 
overlap between algorithms and some are unique. 
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Figure 7: Predicted target site of miR-20b on the APP 3’UTR. Scaled figure showing 
7-mer binding site for miR-20b on the APP 3’UTR. Also shown are the short 5’ UTR, 3.6 
kb coding region drawn to scale.  
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Figure 8: miR-20b reduces APP 3’UTR-mediated luciferase expression. A) Co-
transfection of miR-20b with the full-length APP mRNA 3’UTR results in a reduction of 
APP 3’UTR-mediated luciferase activity, compared to a negative control miRNA 
(p<0.05). B) and C) Mutagenesis of the seed-sequence reverses the 20b-mediated 
reduction of the APP 3’UTR-mediated luciferase activity . 
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MiR-20b reduces APP protein expression in HeLa cells 
Having validated the miR-20b targeting of the APP mRNA 3’UTR, we 
investigated the effect of miR-20b on APP protein expression. Using HeLa cells – a 
consistently transfectable human cell line that expresses APP – we tested the effects of 
four miRNAs – miR-520c-3p, miR-20b, miR-144 and NCM (Figure 9). We also used 
APP siRNA as a positive control to confirm transfection efficiency and experimental 
outcomes. We found that APP siRNA, miR-520c-3p and miR-20b reduced APP levels by 
90%, 60% and 60%, respectively (after normalization to β-actin) compared to Mock- and 
NCM-transfected cells (Figure 9). MiR-144 and NCM did not reduce APP levels in a 
statistical significant manner. Therefore, we found that miR-20b reduces human APP 
levels in mammalian cells of the epithelial type. 
MiR-20b reduces APP levels in a mixed primary human neuronal cell culture 
After confirming the modulation of miR-20b in HeLa cells, we tested thes effect 
of miR-20b in a human mixed neuronal primary cell culture model. Using a previously 
validated model developed in our lab 293 we found that APP siRNA reduces APP 
expression by 50% (Figure 10). MiR-298 reduces APP expression by about 25% 
compared to mock-transfected cells. Co-transfection of an antagomir to miR-20b 
(inhibitor) could reverse the miR-20b-mediated reduction of APP (Figure 10). Although 
the co-transfection of the inhibitor produced a slight increase in APP expression 
compared to mock, this was not statistically significant (p>0.05). Similarly, the slight 
increases observed on transfection with the antagomir alone and with NCM were not 
statistically significant (p>0.05). 
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Figure 9: Transfection of miR-20b results in the reduction of APP expression in 
HeLa cells. APP bands were normalized to β-actin bands using densitometry. N=4, 
p<0.05. Cells were transfected for 72 hours using RNAiMax, cell were lysed, proteins 
were boiled and separated using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Antibodies against APP (clone 22C11) and β-actin were 
used for detection of the protein. APP siRNA was used as positive control, while NCM 
(negative control miRNA) was used to test for non-specific effects associated with 
introducing exogenous miRNA into the cell culture system. 
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Figure 10: miR-20b reduces APP levels, and its inhibitor reverses miR-20b-
mediated reduction of APP. In a primary human cell culture model, the co-transfection 
of an antagomir to mature miR-20b reduced the miR-20b-mediated reduction of APP 
expression. (n=4, p<0.05). The set included here is a representative set of n=4. APP 
siRNA reduces APP expression by approximately 50%, while miR-20b reduced 
expression by ~40% compared to mock- or NCM-transfected cells. ANOVA was used to 
compare different groups. 
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MiR-20b and APP siRNA modulate synaptic connectivity 
We tested whether transfection of miR-20b could modulate, directly or indirectly, 
the synaptic connectivity in the primary human mixed neuronal culture tested. Notably, 
both neurite length and neurite branch points were reduced in a time-dependent manner 
(Figure 11A and 11B) compared to mock- transfected cells. In a separate experiment, we 
tested whether transfection of APP siRNA, had a similar effect at 72 hours post-
transfection. APP siRNA transfection did not reduce neurite branch points or neurite 
length compared to mock transfected cells (Figure 11C and 11D). To test whether this 
change in neuritic length and branch points could result a loss in synaptic activity, we 
tested the effect of miR-20b on the calcium influx of the same human cell culture using 
Fura-2 imaging. We found that miR-20b did not change KCl-induced influx of calcium 
(data not shown).  
MiR-20b reduces soluble Aβ (1-40) levels in cell culture supernatants 
In human primary mixed cells, we tested the effect of miR-20b overexpression on 
levels of soluble Aβ (1-40) peptide. Using a well-validated sensitive ELISA (IBL), we 
observed that miR-20b reduced levels of soluble Aβ (1-40) by about 25% (Figure 12). To 
compensate for individual differences in cell density in different wells, we normalized 
each replicate to the metabolic activity measured from the cell lysate obtained from that 
well (CTG).  
MiR-20b expression is unchanged in post-mortem human brains 
Total RNA was extracted from brain samples and levels of miR-20b were 
measured in these samples. We found that miR-20b expression was not significantly 
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changed across Braak stages of AD (Figure 13). While we did see a slight reduction in 
miR-20b expression between Braak stages III/IV and V/VI, this was not statistically 
significant (p=0.06) (Figure 9).  
When combining all AD groups, we found no difference between miR-20b levels 
in control samples (n=5) vs control (n=20) (Figure 13).  
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Figure 11: Transfection of miR-20b changes synaptic connectivity of neuronal 
culture. Transfection of miR-20b reduces neurite branch points/cluster (A, F) and neurite 
length/cluster (B, F) over a period of four days in vitro, compared to Mock-transfected 
(E). In a  separate experiment, APP siRNA also reduces branch points (C) and neurite 
length/cluster (D) at 72 hours.   
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Figure 12: miR-20b reduces levels of soluble Aβ (1-40). Using cell culture supernatants 
from the primary human mixed brain culture, we showed overexpression of miR-20b 
results in a reduction of Aβ (1-40, A), but not soluble Aβ (1-42) peptide, B) production. 
The optical density values were normalized to the metabolic activity (ATP production) of 
the cells in panel A, whereas in panel B, we were able to calculate absolute values of the 
peptide (n=4, p<0.05). 
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Figure 13: Using RNA extracted from post-mortem adult brains, we measured levels 
of miR-20b from these samples. We found no statistically different effects across 
various Braak stages (A), or when comparing AD against control samples (B). In both 
experiments, equal RNA was used to determine differences in miR-20b levels across 
groups.  
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Discussion 
MiR-20b reduces expression of APP and soluble beta-amyloid (1-40) 
 
The regulation of APP by various miRNA has been shown by various 
laboratories, including our own 232-234,236,238,295. In searching the bioinformatics predictors 
further, we came across miR-20b as a putative modulator of APP expression. Using site-
directed mutagenesis, we confirmed that miR-20b targets the predicted 7-mer site on the 
APPmRNA 3’UTR. We noticed that co-transfecting the mutagenized APP 3’UTR-
containing plasmid along with miR-20b did not return luciferase activity to baseline. This 
is unlikely to be an anamoly due to lower transfection efficiency – as the output of 
Renilla to firefly luciferase should circumvent any problems related to transfection 
efficiency. It is possible that we introduced a new binding site on which endogenous 
miRNA acted to produce a slight (non-significant) reduction in luciferase activity.  
 We showed that miR-20b reduced levels of endogenous APP protein in two 
different tissue culture models. Each cell culture has its own advantages: HeLa cells are 
consistent and reliable in growth and transfection of miRNA,  and express APP at a high 
level. The primary human mixed brain culture used herein is another important primary 
culture model for studying neurodegeneration as it contains neurons, glia and 
neuroprogenitor cells. It is important to note that the magnitude of APP reduction by 
miR-20b differs in the two cell lines. This can be due to two major factors: The 
transfection efficiency of the two cell culture models, and the differential endogenous 
miR-20b levels within each cell culture model. The fact that we did not directly test the 
latter (i.e., miRNA measurements) is a general limitation of the work herein. 
Speculatively, the former factor may play a role. This can be seen by observing that APP 
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siRNA,which provides an idea of the maximal level of transfection efficiency, knocks 
down APP more strongly in HeLa cells than it does in the primary human mixed brain 
cultures. We observed a small, not-statistically significant increase in miR-20b and miR-
20b-inhibitor co-transfected wells. We believe that the antagomir inhibited exo added 
miR-20b, but did not sufficiently buffer endogenous miR-20b levels. In order to test this, 
future experiments should study the effect of miR-20b inhibitor de facto on the 
expression of APP in the cell culture. Our observation that miR-20b does not modulate 
KCl-induced calcium influx may be interpeted in many ways. It’s possible that APP is 
not involved in the calcium response, or, miR-20b does not target voltage-gated calcium 
channels or their specific subtypes. 
 We found that miR-20b did not change in the post-mortem brains of a small 
cohort of age-matched controls vs increasing braak stages. It is important to note that our 
sample size was small (each group had an n=5), and that one needs to repeat the 
experiments with larger samples, at least for the Braak stages I/II and III/IV. 
Additionally, obtaining post-mortem brain samples proves to be a very difficult 
proposition, therefore increasing sample size is a non-trivial issue. The absolute value of 
miR-20b in these samples could not be measured as the miR-20b oligonucleotide 
standards obtained commercially (Sigma) did not show linearity during qPCR assay. On 
visually observing the original vial, it was apparent that a gel-like residue had 
precipitated into the vial, likely due to the PAGE-purification process. 
 It would be interesting to study the level of miR-20b in CSF and serum samples 
from AD patients. Previous work has shown a number of miRNAs that are differentially 
expressed in AD patients. A study that looked at miRNAs in serum of AD, MCI, vascular 
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dementia (VD) and non-AD controls found that 4 miRNA were downregulated in AD 
patients – miR-31, miR-93, miR-146a and miR-143 296. MiR-93 is of particular interest 
because it is in the same miR-17 microRNA precursor family to which miR-20b belongs 
to. However, this report did not reveal changes in miR-20b levels or other miR-17 
precursor family members. In another study, miR-181c was downregulated in AD 
patients, while miR-9 was upregulated in serum samples from AD patients vs Controls 
296,297.  
 While we have shown that miR-20b can reduce APP and soluble Aβ (1-40) levels 
in mammalian cell cultures, the ability of the miRNA to modulate Aβ (1-40) levels in 
animals remains unknown. Two obvious considerations for a discussion of miR-20b as a 
putative drug therapy involve 1. miR-20b’s myriad other targets, and 2. The difficulty of 
delivering miRNA to the brain. MiR-20b has been previously shown to negatively 
regulate Endothelial PAS domain 1 298, vascular endothelial growth factor in the lung 299, 
ephrin B2 and B4 in human placental tissue 300, proteinase-activated receptor-1301, 
phosphatase and tensin homolog302, signal transducer and activator of transcription 3 303, 
IL-1 receptor-associated kinase 4 304, hypoxia-inducible factor 1-alpha 305 and protein 
kinase B 306.  
 These proteins are involved in a variety of functions including neuronal 
development and maintenance, depending on the cell type,  tissues and organs. Therefore, 
the off-target effects of miR-20b warrant serious consideration if it is to be a serious 
candidate as a therapy for reducing APP and Aβ in the brain. One possibility is that miR-
20b targets APP with a greater propensity than it does other proteins, thereby, the effect 
of overexpressing miR-20b would be more significant on APP than the other 
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aforementioned proteins, again which depends on the tissue types. However, to our 
knowledge, there is no comparative study showing miR-20b having a higher binding 
efficiency to APP (or any protein).  
 The next problem is how to increase miR-20b levels in the brain. Three known 
compounds have been reported to increase miR-20b levels. First, 3, 3’-Diindolylmethane 
(DIM) was shown to increase levels of miR-20b in liver mononuclear cells 304. DIM is 
found at appreciable levels in vegetables such as broccoli, and seems to be well tolerated, 
although it’s ability to cross the BBB remains unknown. Second, one year intake of 
Natalizumab increased levels of miR-20b in the blood of patients with multiple sclerosis 
(MS) 307. As a corollary, the same authors deleted the miRNA-106a~363 gene (including 
the miR-20b locus) and found that it severely enhanced experimental autoimmune 
encephalitis – a mouse model for MS – in mice compared to wild-type mice 307. 
Natalizumab is well-tolerated and is capable of crossing the BBB. Finally, prednisone 
acetate was shown to increase miR-20b levels in the serum from patients suffering from 
myasthenia gravis 308.  
 While miR-20b is capable of being modulated by the three aforementioned drugs, 
systemic administration of any of those drugs would cause miR-20b modulation of other 
targets in various organs. For this same reason, systemic increase in miR-20b would not 
be advisable. Therefore, a more selective, targeted increase of miR-20b is warranted.  
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Chapter 6: Specific Aim 2 - To show that miR-298 modulates both endogenous APP 
and BACE1 levels and subsequently levels of beta-amyloid 
Rationale 
 Along with APP, the regulation of BACE1 protein is crucial to the generation of 
potentially toxic amyloid peptides. Therefore, identifying miRNA that target both 
proteins would elucidate an important regulatory element modulating two pivotal proteins 
implicated in Aβ production. Additionally, this miRNA would serve to be a potentially 
powerful miRNA drug target for future AD therapy. 
Our goal was to identify a miRNA that modulates both APP and BACE1 and 
subsequently reduces levels of soluble amyloid-beta peptide(s). The ability to modify 
more than one protein involved in the amyloid pathway would make a miRNA a 
potentially strong candidate for selection for drug trials. Finally, having identified a 
miRNA which modifies these AD-related proteins/peptides, we were interested in the 
possible regulation of the genomic region of the miRNA itself. 
 Based on recent bioinformatics prediction tools, we hypothesized that putative 
dual target miR-298 would bind the APP mRNA 3’UTR and BACE1 mRNA 3’UTR and 
reduce levels of both APP and BACE1 proteins as well as soluble Aβ peptides. 
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Results 
MiR-298 is predicted to target both APP- and BACE1 mRNA 3’UTRs. 
Using three different bioinformatics tools, we found that miR-298 was predicted 
to target both the APP mRNA 3’UTR and BACE1 3’UTR (Table 6). Both target 
sequences on both the UTRs are well conserved across mammalian species (Figure 14) as 
shown by a high context ++ score percentile score. The highly negative binding ΔΔG 
score suggests that the binding efficiency between the mature miRNA and the mRNA 
UTRs is strong as well. There are two predicted miR-298 targets on the APP mRNA 
3’UTR - a 7-mer-m8 target sequence from 549-555 nucleotides and a 7-mer-A1 target 
sequence from 781-787 nucleotides on the APP mRNA 3’ UTR (Figure 14). There is one 
predicted target sequence for miR-298 on the BACE1 mRNA 3’UTR; a 7-mer-A1 site on 
4225-4331 nucleotide positions on the 4.4 kb UTR. There are no predicted target sites for 
miR-298 in either of the coding regions or APP mRNA 5’UTR and BACE1 mRNA 
5’UTR. 
 
 
 
 
 
 
67 
 
Table 6: MiR-298 is predicted to target both APP 3’UTR and BACE1 3’UTR. Six 
separate bioinformatics algorithms predict that miR-298 targets the 3’UTR of APP and 
BACE1. An explanation for each score is also included herein. Crucially, each miRNA 
predictive tool has its own specific parameters for predicting putative miRNA. Some of 
these parameters overlap between algorithms and some are unique. 
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Figure 14: Predicted binding sites for miR-298 on the APP- and BACE1 3’UTRs. 
MiR-298 is predicted to have two possible binding sites on the APP 3’UTR and one 
predicted site on the BACE1 3’UTR. Also shown are the short 5’ UTRs and coding 
regions for both APP and BACE1.  
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MiR-298 targets the APP mRNA 3’UTR 
 Using the same reporter vector described previously, we tested whether miR-298 
targets the APP mRNA 3’UTR. We found that co-transfection of miR-298 along with the 
dual-luciferase vector reduces luciferase activity by 25% compared to both mock-
transfected and a NCM-transfected cells (Figure 15A). MiR-101, a previously validated 
modulator of APP expression was used as a positive control and reduced luciferase 
expression by 30% (Figure 15A). 
 To confirm which of the two target sites was functional, we used site-directed 
mutagenesis procedure to mutate each site separately. We confirmed the mutagenized site 
using the specific DNA restriction digestion followed by gel electrophoresis (data not 
shown). We found that co-transfection of miR-298 with an APP 3’UTR containing the 
mutagenized site-1 showed a reduction in luciferase activity similar to wild-type APP co-
transfected with miR-298 (Figure 15B). On the other hand, co-transfection of miR-298 
with the reporter vector containing the mutagenized site-2 showed no difference in 
luciferase expression (Figure 15C). 
 Together, these results show that miR-298 targets the APP mRNA 3’UTR at the 
predicted site-2. 
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Figure 15: miR-298 targets the APP 3’UTR. Transfection of miR-298 in HeLa cells 
reduces APP 3’UTR-mediated luciferase expression (A), and mutation of target site-1 
does not reverse this effect (B), but mutation of site-2 does (C). The entire seed-site of 
interaction was mutagenized using the Lightning mutagenesis kit (see Methods) and the 
seed-site was initially confirmed by separation on a DNA agarose gel. In all three 
experiments, cells were transfected in a 96-well format for 48 hours and subsequently 
lysed. The ratio of Renilla to Firefly luciferase was calculated and the values obtained 
from the mock condition was set at ‘1’.  
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MiR-298 targets the BACE1 mRNA 3’UTR 
 Previously, in our lab, Dr. Justin Long successfully inserted the full-length 
BACE1mRNA 3’UTR into a dual-luciferase reporter vector 88. We co-transfected this 
reporter vector with mature miR-298 to address whether miR-298 targets the BACE1 
3’UTR into HeLa cells. We found that miR-298 reduced relative luciferase expression by 
30% compared to the reporter alone and a NCM (Figure 16). The slight reduction 
observed when comparing mock to NCM is non-significant (Figure 16).  
 We were unsuccessful in mutagenizing the predicted target site for miR-298 on 
the BACE1 3’UTR (data not shown). 
Human miR-298 reduces APP and BACE1 expression, but mouse-miR-298 does not 
 The sequence of miR-298 itself is not conserved between human and mouse 
genomes. One of the mismatched nucleotides is within the seed-sequence itself – at the 
6th position within the sequence from the 5’ end (Fig 17). In order to address whether this 
lack of conservation would manifest itself in an inability to regulate APP and BACE1 
protein expression, we transfected separately the mature human-miR-298 (hsa-miR-298) 
and mature mouse-miR-298 (mmu-miR-298) into a human glioblastoma cell line that 
expresses both APP and BACE1. 
 We found that hsa-miR-298 reduced expression of APP and BACE1 by 40% and 
75% respectively, whereas mmu-miR-298 did not reduce levels of either protein (Figure 
17). The slight increase observed in mmu-298 expression for both proteins was not 
statistically significant when compared to mock-transfected cells. BACE1 siRNA was 
used as a positive control and reduced BACE1 expression by 80% while having no effect 
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on APP expression compared to mock-transfected cells (Figure 17), as expected. Levels 
of non-target β-actin served as a loading control and remained consistent across 
conditions. 
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Figure 16: miR-298 targets the BACE1 mRNA 3’UTR. Transfection of miR-298 in 
HeLa cells reduced BACE1 3’UTR-mediated luciferase expression. Cells were 
transfected in a 96-well format for 48 hours and subsequently lysed. The ratio of Renilla 
to Firefly luciferase was calculated and the values obtained from the mock condition was 
set at ‘1’. NCM was a negative control miRNA. 
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Figure 17: miR-298 is not conserved across human and rodent species. One of the 
non-conserved sites of the mature miRNA is within the seed sequence (red). 
Overexpression of mouse-miR-298 does not change levels of APP or BACE1 protein, 
whereas human-miR-298 reduces expression of both proteins. 
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MiR-298 reduces APP expression in a mixed primary human cell culture 
Using a mixed neuronal primary human cell culture developed in our lab 293, we 
tested the effect of miR-298 overexpression on levels of endogenous APP. miR-298 
overexpression reduced levels of APP by 50% (Figure 18). The co-transfection of an 
antagomir to miR-298 with miR-298 returned levels of APP to that observed in mock-
transfected cells (Figure 14). The transfection of inhibitor or NCM alone did not change 
expression of APP significantly vs. mock-transfected cells. APP siRNA-transfected cells 
were used as a positive control. APP siRNA reduced APP reduction by 70% compared to 
mock-transfected cells. Levels of β-actin protein served as a loading control and 
remained consistent across conditions, as it was not the target of any miRNA or siRNA 
tested herein (Figure 18). 
MiR-298 reduces BACE1 levels in a mixed primary human cell culture  
 
Using the same mixed neuronal primary human cell culture developed in our lab 
293, we tested the effect of miR-298 overexpression on levels of endogenous BACE1. We 
found that miR-298 overexpression reduced levels of BACE1 by 65% (Figure 19). The 
co-transfection of an antagomir to miR-298 with miR-298 returned levels of APP to that 
observed in mock-transfected cells (Figure 19). The transfection of inhibitor or NCM 
alone did not change APP significantly vs. mock-transfected cells. BACE1 siRNA-
transfected cells were used as a positive control. APP siRNA reduced APP reduction by 
50% compared to mock-transfected cells (Figure 19). β-actin served as a loading control 
and remained consistent across conditions. 
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Figure 18: MiR-298 reduces APP in a primary human mixed brain culture. 
Transfection of miR-298 reduces APP levels, while the co-transfection of an antagomir to 
miR-298 reverses miR-298-mediated reduction of APP protein. (n=4, p<0.05). Cells were 
transfected for 72 hours and subsequently lysed using M-Per buffer. Lysates were boiled 
and separated by SDS-PAGE. Image is a representative set of 4. 
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MiR-298 reduces levels of soluble Aβ peptides and soluble APP in a mixed primary 
human cell culture  
 
Using cell-culture supernatants obtained from Figure 14, we tested whether miR-
298 could reduce levels of soluble Aβ (1-40) and Aβ (1-42) by sensitive and specfic 
ELISA. Indeed, miR-298 overexpression reduced levels of Aβ (1-40) by 60% compared 
to mock-transfected cells, while co-transfection of the inhibitor reversed the miR-298-
mediated reduction of Aβ (1-40) (Figure 20A). APP siRNA also reduced Aβ (1-40) while 
NCM didnot (Figure 20A).  
Congruently, miR-298 reduced levels of Aβ (1-42) by 60% compared to mock-
transfected cells and the co-transfection of the inhibitor reversed this reduction. APP 
siRNA reduced levels of Aβ (1-42) by 50%, whereas transfection of the 298 antagomir 
alone or NCM alone had no effect on Aβ (1-42) levels (Figure 20B). 
While we observed a reduction of miR-298 in APP levels obtained from cell 
lysates, we were interested in whether miR-298 could modulate levels of the truncated 
soluble APP (sAPP) obtained from cell culture supernatants. We transfected miR-298 and 
collected cell culture supernatants at 24-hour time intervals upto 4 days. Interestingly, 
miR-298 reduced levels of sAPP at 48 and 72 hours post-transfection, compared to mock-
transfected cells harvested at the same time points (Figure 20D). While time points of 24 
and 96 hours showed a slight reduction in sAPP levels, this reduction was not statistically 
significant in both the cases (Figure 20D). 
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Figure 19: MiR-298 reduces BACE1 in a primary human mixed brain culture.  
MiR-298 reduces BACE1 levels , while co-transfection of an antagomir to miR-298 
reverses miR-298-mediated reduction of BACE1 protein. (n=4, p<0.05). Cells were 
transfected for 72 hours and subsequently lysed using M-Per buffer. Lysates were boiled 
and separated by SDS-PAGE. Image is a representative set of 4. 
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Figure 20: In a primary human mixed brain culture, miR-298 reduces levels of 
soluble beta-amyloid (1-40) and (1-42). Transfection of miR-298 reduces levels of both 
Aβ (1-40, A) and Aβ  (1-42, B) as measured by sensitive ELISA (IBL). Optical density 
for both ELISA was compared against a standard curve of known amount of peptide to 
obtain concentration. Values obtained from mock-transfected cells were normalized as 
A 
D 
C 
B 
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‘1’ and used to generate graphs obtained. Congruently,  co-transfection of an antagomir 
to miR-298 reverses miR-298-reduction of both soluble beta-amyloid peptides. (n=4, 
p<0.05). Using conditioned media, we also show that miR-298 reduces levels of soluble  
APP. (n=3, p<0.05) at 48h and 72 hr significantly. All time points showed a slight 
reduction, but 24h and 96h did not produce statistically significant effects. For the soluble 
APP experiment, equal volumes of conditioned media were separated by SDS-PAGE and 
probed with anti-APP (22C11).   
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SNPs in the MIR298 gene boundary in a large cohort of human AD patients 
 
Using plasma expression data available from the ADNI cohort, we identified 
SNPs present within a +/- 5kb boundary of the MIR298 gene. We found 6 families of 
SNPs in this region (Figure 17). We also found that one of these SNPs rs6070629 was 
significantly associated with CSF phosphorylated tau, whereas, another SNP rs79259988 
was significantly associated with CSF Aβ (1-42) (Figure 21). This is an important 
finding, which connects our mechanistic and functional work directly to the patients.  
 MiR-298 reduces expression of specific isoforms of tau 
In order to test whether miR-298 may target tau, we further examined the protein 
cellextracts from two separate experiments conducted in human primary mixed brain 
culture. Notably, tau protein expression of the 55kDa band was reduced significantly in 
miR-298-transfected cells compared to mock-transfected cells (p<0.05) (Figure 22), 
whereas NCM-transfected cells showed no reduction in 55 kDa tau protein (Figure 
22A,B). We also observed a doublet at 48 kDa, but the expression of this tau isoform was 
not changed significantly in miR-298 transfected cells (Figure 22A,C). 
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Figure 21: Two SNPs in proximity of MIR298 gene are significant associated with 
AD CSF biomarkers. Two SNPs in the proximity of the MIR298 gene boundary are 
significantly associated with CSF p-tau, and CSF beta-amyloid (1-42). This data was 
generated by Dr. Kwangsik Nho using patient samples available from the ADNI cohort 
(see methods). 
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Figure 22: MiR-298 reduces total-tau expression selectively. In a primary human 
mixed brain culture, transfection of miR-298 significantly reduced levels of the 55 kDa 
form of total tau, but not the 48 kDa isoform. N=8, p<0.05.  
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Discussion 
 
MiR-298 reduces APP and BACE1 by targeting the 3’UTR mRNA 
We identified miR-298 as a negative regulator of APP levels in mammalian, 
including human cell cultures. Using a luciferase reporter construct containing the full-
length APP or BACE1 3’UTR, we  showed in separate experiments that co-transfecting 
miR-298 with the reporter reduced luciferase reporter activity markedly, which suggests 
that miR-298 targeted both the APP and BACE1 3’UTRs. Multiple bioinformatic tools 
predicted that miR-298 might have two target sites on the APP 3’UTR and one on the 
BACE1 3’UTR. We separately mutagenized both sites on the APP 3’UTR, and observed 
that mutation of the site 2 (781-787) reversed miR-298- mediated reduction of luciferase 
reporter activity. This result confirmed that miR-298 target the APP 3’UTR at site 2. It is 
possible that there are other noncanonical sites on the 3’UTR which may contribute 
synergistically to miR-298 ‘s targeting of the APP 3’UTR. However, this remains 
conjectural, as we were unable to find predictions of noncanonical sites on the 
APP3’UTR. We also did not notice predictive algorithms that would suggest miR-298’s 
binding sites on the 5’ UTR or the coding sequence of APP. Therefore, we believe that 
miR-298’s function as an APP regulator is a consequence of its action on site-2 of the 
APP 3’UTR. 
 While we showed that miR-298 targeted the BACE1 3’UTR, we were unable to 
successfully mutagenize the single predicted site for miR-298’s binding on the BACE1 
3’UTR. Therefore, we cannot conclusively state that miR-298’s action on BACE1 is 
mediated via the predicted site. Like APP, we did not find predicted sites for miR-298 on 
the BACE15’UTR or the coding region. Noncanonical binding of miR-298 on the 3’UTR 
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was also not predicted. Therefore, we believe that miR-298 regulates BACE1 expression 
by targeting the 3’UTR, most likely at the predicted site. 
 We conclusively showed that miR-298 targets APP and BACE1 protein 
expression in mammalian cultures. First, we showed that miR-298 reduced levels of APP 
and BACE1 protein in U373 – a commonly used glial cell line. Using our human primary 
mixed brain culture developed in our lab, we were able to test the effect of miR-298 on 
endogenous protein expression in primary cultures containing neurons, glia and 
neuroprogenitors, which, to some extent mimick the brain cellular composition. We 
showed that miR-298 significantly reduced expression of both proteins in this tissue 
culture model, which is highly relevant to the CNS context. Given that we showed miR-
298’s reduction of APP and BACE1 proteins in human glial cells, it is interesting to 
speculate the reduction we observe in our primary brain culture involves reduction of 
neuronal APP and BACE1 as well. We were unable to successfully transfect miR-298 
into differentiated human NB cells and therefore cannot ascertain the specific ability of 
miR-298 to regulate neuronal APP. The specific reduction of proteins by miR-298 
remains a future experiment that can be performed by improving transfection efficiency 
in differentiated NB cells, by possibly using lentiviral delivery of miR-298. In summary, 
miR-298 regulates glial APP and BACE1 expression and possibly neuronal APP and 
BACE1. 
 We also conclusively showed that overexpression of miR-298 reduced both 
soluble Aβ (1-40) and Aβ (1-42) peptides. In accordance with the amyloid hypothesis 
38,89,309, reduction of these two peptides is relevant to understand neuropathogenesis of 
AD. It is important to consider testing the reduction of the two peptides by miR-298 o in 
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relevant in vivo models. This is due to the fact that individual levels of miR-298, APP 
and BACE1 are important to regulating whether Aβ (1-40) and Aβ (1-42) can be reduced 
sufficiently. In other words, miR-298 levels have to be high enough to produce a 
subsequent enough reduction of APP, BACE1, Aβ (1-40) and Aβ (1-42), and which 
depend on a particular cell type or brain region involved. A future direction of work 
remains to measure levels of miR-298, APP and BACE1 in different regions of human 
brain. This would allow us to estimate the ratio of the  the miRNA required to produce a 
subsequent change in protein expression (and by extension, Aβ (1-40) and Aβ (1-42)). 
 After showing the regulation of APP and BACE1 by miR-298, we investigated 
the possible regulation of MIR298 gene itself in a large cohort from Alzheimer’s patients 
at different stages. Scanning a region downstream 5kb upstream/downstream of the short 
~100 nucleotide region, on chromosome 20, corresponding to the precursor miRNA, we 
found a linkage disequilibrium (LD) block of SNPs expressed in the ADNI cohort. 
Interestingly, two of these SNPs significantly associated with two known markers of AD 
pathology – CSF Aβ (1-42) as well as CSF phosphorylated tau. It is important to note that 
both SNPs are outside the MIR298 boundary. Therefore, it may be possible that the 
associations of these SNPs is independent of miR-298’s putative role in AD. However, it 
is also possible that these two SNPs are involved in the regulation of miR-298 
expression, and, by extension, the CSF biomarker hallmarks observed in the ADNI 
cohort, through an yet unknown mechanism. 
 Another puzzling observation is that while we could explain possibly the 
MIR298-associated SNP in relation to CSF Aβ (1-42) changes, we could not how miR-
298 targeted phospho-tau. Although we did not test phospho-tau directly, we showed that 
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miR-298 negatively regulated total tau levels. Even though we were able to show miR-
298’s regulation of tau protein, commonly used bioinformatics algorithms, such as 
TargetScan, did not predict miR-298 as having a canonical binding site on the tau 3’UTR. 
We did, however, find a non-canonical site, which predicted that miR-298 targeted the 3’ 
UTR in a manner inclusive of it’s first nucleotide as a part of the seed sequence.  
 As a future direction, we would like to confirm whether the SNPs we identified 
play a role in the expression of miR-298. One way would be to insert the full length 
immediate to and including the MIR298 gene into two overexpression vectors – each 
having one version of the SNP we identified. We would then transfect these vectors and 
measure miR-298 levels in neuronal cultures. We could also co-transfect each mutated 
plasmid along with APP 3’UTR to test if the putative difference in miR-298 results in 
differences in abrogation of miR-298’s reduction of APP and BACE1. 
 We have shown that miR-298 regulates three proteins involved in the 
pathogenesis of AD: APP, BACE1 and tau. It is important to test these effects by 
miRNAs translatable into the regulation of AD in humans. It would be interesting to posit 
miR-298 as an evolutionary tool to repressing the aforementioned proteins for natural 
selection. A small bit of evidence for this idea is that the sequence of mouse-miR-298 is 
different from human-miR-298 – one of those differences being within the seed sequence 
of the miRNA. We were able to show that mmu-miR-298 was incapable of regulating 
human APP and BACE1, thereby suggesting that the sequence specificity of hsa-miR-
298 is required for the regulation of those two proteins. Fascinatingly, using the DBSNP 
site on pubmed, we observed a SNP within the coding region of the MIR298 gene – 
specifically located within the region corresponding to the seed sequence. Unfortunately, 
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the expression of this allele was very low, and we were unable to find out any 
information about the individuals (s) expressing this SNP. The phenotypic data of 
individuals expressing this SNP would be an important data to understand the role of  
miR-298 in AD.   
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Chapter 7: Specific Aim 3 – To study levels of NEP protein in various cell types and 
tissues and identify putative miRNA that target its 3’UTR 
Rationale 
 
There is data emerging implicating Aβ deposition in early childhood that may 
later contribute to Alzheimer-like pathogenesis 310,311.  Therefore, it seems Aβ-
degradation may be important across a person’s life time. In accordance with this, 
measuring NEP levels from human samples across development and at various ages 
would help understand the disease progression. To date, while levels of different AD-
related protein have been studied in autopsied human brain tissue specimens 142,312-314, the 
protein levels in human fetal tissues have been unexplored. Moreover, gene expression of 
NEP in the plasma of AD patients is unknown. Finally, while extensive work has looked 
at the promoter region and SNPs associated with it 155,156,315,316, identification of possible 
regulatory regions in the 5’ and 3’ regions proximal to the NEP gene remains unclear. It 
is unknown whether the long 3.2 kb  of NEP mRNA 3’UTR may have cis- or trans-
lements that may target this region and perturb protein expression. Our work herein 
attempts to address these gaps in the field. 
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Results 
Detection of NEP protein 
 
Using western blotting probing with antibodies raised against various epitopes 
across the NEP protein (Table 2), we attempted to detect NEP protein in lysates obtained 
from adult human brain (lane 1) and the positive control of rat kidney (lane 2) (Figure 
23). We found that the among seven antibodies tested, we were unable to detect NEP 
succesfully at the expected molecular weight (Mw) using any of the antibodies. Three of 
the antibodies (112AP, 131AP and RnD MAB1126) showed immunoreactivity at lower 
Mws of 60 kDa or 50 kDa (Figure 23) than ~100 kDa. Three antibodies (131AP, 141AP 
and RnD) showed a distinct NEP band at the expected Mw of ~100 kDa (Figure 23). 
Based on the appropriate band at the right Mw, as well as the immunoreactivity observed 
in the adult brain lane, we selected to use the RnD antibody for further examinations. 
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Figure 23: Western blotting to detect NEP in human adult brain. Three antibodies 
detect NEP at the right Mw in rat kidney samples, but no antibody detects NEP at the 
right Mw in adult brain. Six different commercially available antibodies were used to 
detect NEP Three antibodies (131AP, 141AP and RnD) showed a band in the positive 
control rat kidney (lane 2) sample. 
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Figure 24: Detection of NEP in differentiated human neuroblastoma cells using 
various antibodies. Hoechst stain (a,c,e,g,h,j) and NEP immunoreactivity was tested 
with NEP antibodies 101AP (b),112AP (d), 131AP (f), 141AP (h), 151AP (j), 161AP (l). 
NEP was successfully detected by ICC using antibodies 161 AP and possibly 151AP. 
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Detection of NEP in neuronal cells 
 
 Using immunocytochemical (ICC) analysis probing with the same antibodies used 
for western blotting, we tested differentiated human neuroblastoma cells (NB) for NEP 
expression. Hoechst staining was used to visualize nuclei, whereas cy3-conjugated 
antibodies were used to visualize NEP protein expression. We observed that antibodies 
151AP and 161AP showed the strongest immunoreactivity with NEP protein (Figure 24 j, 
l). Separately we observed that the secondary antibody (goat anti-rat) alone showed no 
immunoreactivty, nor did the RnD antibody used earlier (Data not shown). 
Cellular  detection of NEP protein using western blotting 
 
 NEP protein has been very difficult to detect in cell cultulre models. We tested 
various commonly used human and rodent cell lines to detect NEP. Using the RnD 
antibody we selected from the results shown in Figure 23, we found that no cell line 
expresses NEP at the expected molecular weight. We observed distinct bands at ~75 kDa 
band in NB and HEK-293T cells (Figure 25). We observed a ~50 kDa band across all the 
cell lines tested, but this was later found to be a secondary-antibody-related band. NEP 
was detected at the right molecular weight in rat kidney lysate (Figure 25). Both beta-
actin and tubulin were used as loading controls. 
 To address whether the lysis buffer conditions contributed to the difficulty in 
detecting NEP, we used different lysis buffer formulations to lyse LNCaP cells and 
prepare cell extracts. We detected a faint NEP band under all 5 different lysis conditions; 
namely M-Per buffer alone, M-per buffer enriched with protease inhibitor and/or 0.1% 
SDS, or RIPA buffer (Figure 26). In all formulations, faint NEP immunoreactivity was 
observed at the expected molecular weight (~100-110 kDa) when 15 ug of protein was 
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loaded, and no immunoreactivity was observed when 3 ug of protein was loaded. A lower 
molecular ~75 kDa band was observed in all lanes, including the human neuroblastoma 
and U373 cell extracts (Figure 26). 
 
Detection of NEP in rodent tissues 
 Using tissue obtained from adult rats, we tested NEP immunoreactivity in protein 
extracts from various rodent tissues. NEP protein expression was the highest in rat 
kidney, intermediate in lung, low in the cortex and undetectable in the hippocampus and 
liver extracts (Figure 27). Interestingly, we observed an opposite trend when probing with 
APP and BACE1, that is the tissue extracts such as kidney, which had high levels of 
NEP, showed limited APP and BACE1 expression (Figure 27). Conversely, tissues such 
as cortex and hippocampus which showed high APP and BACE1 expression, showed 
very low NEP expression. β-actin was used as a loading control (Figure 27).  
 We tested the hypothesis whether an inhibitor to the enzyme was present in 
cortical and hippocampal CNS-derived samples, which could explain the lack of NEP 
expression in CNS. For this, we combined cortical and hippocampal samples with kidney 
and lung samples and subsequently boiled in Laemmli sample buffer and separated by 
SDS-PAGE. We did not observe quenching of NEP protein expression in lung and 
kidney samples (Figure 27). However, when combining cortical tissue or kidney tissue 
with lung tissue, we observed bands of distinct molecular weights. This result indicated 
that NEP in the kidney is expressed at a slightly higher Mw than NEP in the cortex or 
lung (Figure 27). 
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Figure 25: Different cell lines probed with anti-NEP (RnD-monoclonal) antibody). 
β-actin and α-tubulin serve as  loading controls.  R:Rat, H:Human. Lysates obtained from 
different cell lines were boiled and separated using SDS-PAGE and probed with anti-
NEP (RnD). As can be seen, while other MW bands appeared, only the positive control 
(kidney, lane 1) showed a band at the right MW - ~100 kDa. 
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Figure 26: NEP expression using different procedures.  Lanes 1-10 were loaded with 
LNCaP cells.  Lanes 1-5 were loaded at 15ug in accordance with different extraction 
techniques.  Lanes 6-10 were loaded with 3ug, in accordance with the appropriate 
technique.  U373, Differentiated NB, rat cortex and rat kidney are the final lanes. 
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Figure 27: Tissue specific expression of NEP, APP and BACE1. Representative 
images after probing with antibodies targeting APP, NEP and BACE1. β-actin was used 
as a loading control.  Clear NEP bands were observed with lung and kidney, whereas a 
faint NEP immunoreactivity was observed with cortex tissue. Combination of tissues 
confirms that NEP in lung-derived tissue is of a higher MW than that from kidney and 
cortical tissue. 
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Differential expression of NEP in fetal tissue and relationship with beta-amyloid 
 
 Using cell culture lysates obtained from legally aborted human fetal tissues, we 
studied the expression of NEP in various fetal organs/tissues using western blotting. NEP 
protein was highly expressed in the kidney, had intermediate immunoreactivity in heart, 
lung and thymus tissue, and low expression in adrenal cortex, brain and spleen/pancreas 
(Figure 28A).  
 In order to confirm our result further, we also used sensitive sandwich ELISA 
(RnD) for NEP protein and found that the pattern of expression was consistent with 
results obtained from western blotting (Figure 28B). 
 To corroborate results observed with the rodent tissues, we probed the blot 
sequentially with antibodies targeting APP and BACE1. APP was expressed high in the 
brain and kidney, intermediate in the heart, lowl in the thymus and lung, but undetectable 
in the adrenal cortex and spleen/pancreas (Figure 28A). BACE1 was expressed high in 
the brain, intermediate in the kidney and adrenal cortex, and low to negligible  in the 
other tissues under the conditions employed herein (Figure 28A). 
 Given the differences in APP, BACE1 and NEP expression, we measured levels 
of Aβ (1-40) and Aβ (1-42) peptides in the tissue protein extracts. We found the highest 
levels of Aβ (1-40) in the brain (1808 pg/ug of protein), intermediate levels in the kidney 
(25.04 pg/ug of protein) and lower levels in other tissues (Figure 28B). Aβ (1-42) was 
only detectable in the brain (Figure 28B). 
Finally, we ran a correlation study between NEP expression and Aβ (1-40) levels 
as shown by ELISA, and found that while tissues tended to have a direct correaltion 
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between the two proteins, the brain data did not fit a direct correlation and remained an 
outlier (Figure 28C). 
We performed a NEP enzymatic assay using the same samples used in our 
western blotting and ELISAs (data not shown). Interestingly,  the trend of the enzyme 
activity was similar to that observed by western blotting and ELISA. Specifically, the 
fetal kidney and lung extracts showed the highest  NEP enzymatic activity among the 
tissue extrcats tested, with brain showing a lower, but measurable, level of activity. 
Absolute values were not calculated as the recombinant NEP enzyme did not produce the 
linearity to satisfy requirements. 
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Figure 28: Differential expression of NEP in human fetal tissue. Brain, 
spleen/pancreas, adrenal cortex, heart, kidney, thymus and lung were loaded along with 
LNCaP positive control. NEP immunoreactivity was highest in kidney (A). The pattern of 
tissue-specific expression was confirmed by an ELISA measuring NEP expression (B). 
Using ELISA, we also measured levels of beta-amyloid in these tissues and found the 
highest levels of both peptides in fetal brain. We plotted levels of NEP measured as a 
function of the amount of protein in the assay (C). We found that while all tissues follow 
a general linear trend, brain-tissue is an outlier. 
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NEP gene expression is increased in AD patients 
 
Using gene expression data from a large cohort of human patients, which was 
stratified by disease progression, we measured NEP gene expression. We found that the 
expression of 2 out of 4 NEP transcripts increased between control and AD samples 
(Figure 29A, B). There was no difference between the control group against early or late 
MCI. Expression of other Aβ-degrading enzymes such as IDE and MMPs were also 
measured, but found to be either unchanged or at levels below threshold of detection for 
analysis. As a proof of principle, we successfully detected NEP protein in human plasma 
samples (data not shown). 
 
NEP protein remains unchanged in a small cohort of AD brains 
 
Using a commerically available NEP ELISA kit , we measured levels of NEP in 
lysates collected from homogenized autopsied brain tissue specimens. These samples 
were stratified by Braak stages. We found no significant difference in NEP expression 
across Braak stages (Figure 30). We also did not observe a difference when all AD 
samples were combined as one group and compared against non-AD , age-matched 
controls (Figure 30). 
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Figure 29: Peripheral gene expression of two transcript variants of MME (A,B) 
measured by microarray. Dashed line is used to indicate level of the mean of control 
for each transcript. *p<0.05 . This data was generated by Dr. Kwangsik Nho using 
samples available from the ADNI cohort. MME AD transcripts are significantly 
increased compared to the control group. Early MCI (EMCI) and late MCI (LMCI) are 
not significantly increased.  
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Figure 30: Level of NEP is unchanged in AD vs control brain. Samples were 
homogenized (see Methods), and sensitive ELISA was performed on these samples. No 
significant effect was seen either on comparing across Braak stages (A), or combining all 
AD diagnosis as one group, compared to control (B). Data were plotted by dividing each 
data point by the mean of the values obtained from the non-AD group. 
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Figure 31: SNPs found in proximity to the NEP gene from a large cohort of AD 
patients. Using data available from the ADNI cohort, genomic region +/- 5kb of the 
MME gene was examined for SNPs. This data was generated by Dr. Kwangsik Nho from 
data available from the ADNI cohort. 
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Insertion of NEP 3’UTR into a reporter vector changes baseline luciferase activity 
in different mammalian cell lines 
In order to test for the post-transcriptional regulation of NEP 3’UTR, we inserted 
the full-length NEP 3’UTR into a psiCheck2 reporter dual-luciferase reporter vector. We 
then transfected either the vector or the vector-containing the full-length 3’UTR into 
mammalian cell lines, such as Hela and NB cells, and measured their reporter (luciferase) 
activity in the corresponding cell lysates  (Figure 32).  An insertion of the NEP 3’UTR 
produced a 300% increase in reporter activity in HeLa cells (p<0.05), a 50% increase in 
U373 cells (p<0.05), a 300% increase in naïve NB cells (p<0.001) and finally a 50% 
increase in differentiated human NB cells (p<0.001) (Figure 32).   
Various miRNA are predicted to target the NEP 3’UTR 
 
In order to address if the increased NEP expression may be due to positive 
regulation by a specfic miRNA, we looked for predicted miRNA that may target the NEP 
3’UTR. At least six  miRNAs, miR-204, miR-211, miR-9, miR-128, miR-181 and miR-
216,  were predicted to target NEP-3’UTR, by at least 4 different miRNA prediction 
algorithms (Table 7). We also mapped the predicted binding sites for each miRNA on a 
NEP 3’UTR drawn to scale. MiR-9 and miR-128 have two possible binding sites on the 
NEP 3’UTR, whereas the other 4 miRNAs have one predicted site (Figure 33).  
 
MiR-216 reduces NEP 3’UTR activity 
 
In order to test whether the NEP 3’UTR is regulated by any of the predicted 
miRNA, cells were co-transfected with the luciferase reporter contianing the NEP 3’UTR 
with one of the abover miRNAs, at a time. We observed no miRNA postively regulating 
the NEP 3’UTR, and miR-216 reducing luciferase reporter expression of the NEP 3’UTR 
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by 25% (p<0.05) (Figure 34). The other miRNA tested had no effect on NEP 3’UTR-
mediated luciferase activity. 
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Figure 32: Effect of insertion of NEP 3’UTR on the expression of luciferase activity. 
The NEP 3’UTR was inserted into a PsiCheck2 vector. The control vector and UTR-
containing plasmid were transfected into HeLa (a), U373 (b), SK-N-SH (c) or 
differentiated SK-N-SH d). Cells were lysed after 48 hours and luciferase activity was 
assessed. Renilla luciferase activity was normalized to Firefly luciferase activity and the 
mean of luciferase activity in the vector was set at 1.  In glial and neuronal cells, the 
insertion of NEP 3’UTR significantly increased luciferase expression. 
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Table 7: Identification of putative miRNA targeting the NEP 3’UTR using five 
different bioinformatics algorithms.  
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Figure 33: Various miRNA are predicted to target the NEP 3’UTR. Predicted 
binding sites for these miRNA are shown on a scaled NEP 3’UTR. MiR-9 and miR-128 
are predicted to have two putative binding sites on the NEP 3’UTR whereas the other 
miRNA have a single putative binding site. 
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Figure 34: MiR-216 reduces NEP 3’UTR mediated luciferase expression in HeLa. 
cells. A reporter construct containing the full-length NEP 3’UTR co-transfected with 
predicted miRNAs. Compared to both negative control miRNAs, miR-216-transfected 
cells showed a reduction in luciferase activity (n=5, p<0.05). 
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Discussion 
 
Understanding the gene and protein expression of NEP in tissues of different 
origins would help explain why certain tissues are more prone to Aβ insult than others. In 
accordance with this, we measured the adult rat and fetal human tissue-specific 
expression of NEP. Moreover, we explored whether NEP gene expression may differ 
between AD and control subjects and whether the gene may be under post-transcriptional 
regulation. 
We observed differential NEP expression in various rat organs. We also observed 
NEP immunoreactivity at different molecular weights which could be due to different 
post-translational modifications and/or different splice variants. It has been previously 
show type 2b predominates in the kidney, while type 1 predominates in the brain 317. 
However, given that the splice variants are independent of the coding region, we believe 
that our results are a consequence of post-translational modification – specifically 
glycosylation – of the NEP protein. Interestingly, we observed an inverse correlation 
between the expression of NEP and the expression of APP and BACE1. It has been 
previously suggested that the amyloid intracellular domain (AICD) drives the expression 
of the NEP promoter in a presenilin-dependent manner 318,319. In other words, there may 
be a feedback loop involving the secretase enzymes, their products and the expression of 
NEP.  This complicated feedback loop begs the question – which comes first – the 
increased NEP expression resulting in lower amyloid load, or does the amyloid load 
initially perturb NEP expression? Future work should address this question of initial 
causation. 
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NEP transcript is highly expressed in the fetal lung 320 and showed tissue-
dependent transcription across various fetal tissues 315, however, it’s protein expression in 
fetal lung had not been studied. We also observed differential expression of NEP in 
various human fetal tissues. In both human fetal and rat kidney, NEP is expressed at 
higher levels than other tissue studied (Figure 5, 6). We also observed strong NEP-
immunoreactivity in the thymus, which is consistent with previous work suggesting high 
abundance of type 1 NEP mRNA in this region 315. As far as levels of Aβ40 and Aβ42 in 
these tissues are concerned, while Aβ40 was observed at measurable levels in all tissues 
tested, Aβ42 levels were detected only in the brain. While the fact that all our data is 
from one individual is an important caveat, we can make certain interesting observations. 
First, the agreement between western blot and ELISA is remarkably strong; NEP is 
expressed high in certain peripheral tissues, such as kidney and lung, and significantly 
low in the brain. Second, while one might expect NEP and Aβ40 to have an inverse 
relationship, plotting NEP expression of peripheral tissue against that of Aβ40 measured, 
suggests a linear relationship between them. This may partly be due to NEP’s proclivity 
to cleave multiple substrates, such as angiotensin, insulin and bradykinin, in peripheral 
tissues. The outlier to the linear relationship is fetal brain tissue samples. While NEP is 
measured at a level similar to adrenal cortex, the amount of Aβ40 observed in the brain is 
over 300,000 times more than that observed in adrenal cortex. This anecdotal observation 
supports the idea that perhaps Aβ40 clearance in the brain requires the concerted effort of 
other Aβ-degrading enzymes. A caveat to this claim would be that our results are 
contingent on an assumption that Aβ clearance mechanisms are the same in both fetal and 
adult brains, which warrants further research. 
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Having examined the expression of NEP in adult rodent and human fetal tissues, 
we examined the expression of NEP in the ADNI cohort and in the brains of a small 
cohort of post-mortem brains available to us. Previous work has shown that it is possible 
to measure NEP in the periphery in mice and non-human primates 321,322; however, we 
looked at expression in a large cohort of AD patients and healthy controls. NEP was 
increased in AD patients vs controls. In accordance with the ‘peripheral sink hypothesis’ 
323,324, sequestration of Aβ can help clear Aβ in the brain. Therefore, increased NEP in the 
periphery would be theoretically beneficial. There are reports that circulating peripheral 
NEP can reduce plaque burden in the brain 279,325, however, there are also conflicting 
reports regarding the ability of peripheral NEP to clear brain Aβ 321,322. Therefore, while 
the importance of peripheral NEP expression to Aβ clearance remains controversial, we 
are the first to report the increased NEP expression in the plasma. It is important to note 
that while the effect size is not large, the result is not simply a statistical phenomenon – 
as other proteins involved in AD (such as APP and BACE1) did not show a change. 
Moreover, another Aβ-degrading enzyme, ECE1, did show an increase in AD v healthy 
controls (HC). This result warrants further exploration to understand the importance of 
the sink hypothesis to AD.  
We also identified various SNPs spanning the MME gene as well as the 3’ and 5’ 
region proximal to it. Previous work has shown that rs3736187 – a SNP located on the 
NEP gene is associated with a decreased risk for AD326. In our own ADNI cohort, one 
SNP (rs111276850) showed a significant association with CSF Aβ (1-42) and total-tau. 
Given that this SNP is located at the 5’ end of the gene, this SNP may act as a cis-acting 
regulatory element influencing NEP expression. Alternatively, it may encode a trans-
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element acting on a different gene. Either way, this novel region warrants further 
examination.  
We did not observe a change in NEP protein expression across a brain cohort 
stratified by Braak stage. Given the small sample size per group as well as the 
heterogeneity among samples, this result is not altogether surprising. We observed a 
marked heterogeneity in NEP levels in the control group. Given that these control 
subjects were age-matched to AD patients, it is interesting to speculate the reasons for 
this observation. Perhaps the perturbations in NEP expression reflect a dynamic turnover 
of the protein that is impaired in AD patients – in support of this, levels of NEP protein 
(except for one outlier) are very similar in AD brains. Speculatively, perhaps a dynamic 
turnover of NEP protein is required to prevent the onset of AD. 
 Along with drug therapies targeting NEP 327-331, our group (and others) has 
conclusively shown that it is possible to modulate the expression of proteins involved in 
AD by identifying specific miRNA 88,233,236. MiRNA are short, non-coding RNA species 
that target the 3’UTR of associated RNA. In accordance with this, we tested whether the 
NEP 3’UTR was under post-transcriptional regulation by endogenous factors in various 
cell types. We found that induction of the NEP 3’UTR resulted in increased reporter 
luciferase expression in different cell lines. While other candidates, such as long non-
coding RNA cannot be ruled out, it is possible that miRNA are responsible for this 
positive regulation of the NEP 3’UTR. Using prediction algorithms, we have identified 
five such potential candidates in Table 1. We identified miR-216 as a putative regulator 
of NEP protein.  
116 
 MiR-216 has been implicated in other non-NEP modulating functions. It has been 
shown that miR-216 levels are modulated in a transgenic mouse models of pancreatic 
adenocarcinoma 332, and the knockout of a ~30 kb region on chromosome 11, which 
includes the MIR216 gene is embryonically lethal 332. Additionally, the 3’UTR of GABA 
receptor type A was shown to have a putative target site for miR-216 333, although the 
effect of miR-216 on GABA-A expression was not studied. 
 Another limitation is that our protein data from fetal tissue and post-mortem brain 
is contingent on the immunoreactivity of the NEP ELISA. Finally, we did not measure 
mRNA levels of NEP in the post-mortem brain to corroborate our protein data. 
NEP is a protein that has been implicated in Alzheimer’s disease 159,312,314,334. 
Therefore, measuring NEP expression and activity in fetal and adult brain tissues as well 
as other periphery and CNS tissues would help in unveiling the biochemical mechanism 
of amyloidosis and in turn A-mediated neurodegeneration seen in AD subjects.  
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Chapter 8: Overall discussion and future directions 
 
 We have identified structurally and characterized functionally several specific 
miRNA species that can modulate key proteins involved in the pathogenesis of AD. 
Therefore, it is important to discuss the translatability of the work, and future  potential 
for miRNA therapy. 
The first hurdle in miRNA therapy is the fact that naked RNA is rapidly degraded 
by ribonucleases 335. To improve the stability of RNA moities, technologies such as 2’O-
methyl RNA (2’-O-Me) 336 and locked nucleic acid (LNA) 337 were developed. While 
these moities improve the stability of the RNA strands, they do not facilitate delivery 
across the BBB 337. By sheating the miRNA in lipid and cationic complexes, miRNA and 
siRNA have been successfully transported across the BBB.  
 Lipid-based reagents, such as lipofectamine, are successfully utilized to deliver 
miRNA across the cell membrane in various cell culture models, as we have shown it. 
However, this methodology may not be suitable for working with biologic fluids due to 
high salt concentration and other considerations 337. Another difficulty is that lipid-based 
complexes can produce an unwanted immune response, often due to the nonspecific 
activation of inflammatory cytokines 338,339. In order to circumvent these problems, 
neutral lipid emulsion (NLE) – cholesterol mediated cationic solid nanoparticles 
formulated with esterquat and stearylamine – was developed . This formulation has been  
shown to facilitate small molecule delivery across the BBB340. Alternatively, RNA 
complexed to a short peptide obtained from the rabies virus can be delivered into 
neuronal cells, by specific binding to acetylcholine receptors. This method has been 
shown to be capable of reducing mouse prion protein in vivo341 .  
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 Polyethylenimine (PEI)-based RNA delivery utilizes cationic complexes, which 
retain a positive charge. This positive charge provides a binding motif for the negative 
charge on unknown cell surface protein 342,343. This binding, in turn, facilitates complexes 
to presumably undergo endocytosis and deliver RNA. As a proof of concept, PEI-
conjucated-miR-124a was injected into the tail vein of mice, which was shown to 
increase miR-124a levels in the brain 344. As a caveat, mannitol was used to help increase 
permeability of the BBB. 
 Other delivery systems such as exosomes, which can easily cross the BBB 
without eliciting a toxic immunse response 11,345,346, dendrimer-based delivery 347,348, 
chitosan 338,349,350 and degradable polymer-coated gold nanoparticles 351 are currently 
being developed for better delivery of RNA across the BBB. 
 Limited work has shown the viability of deliverying RNA via the intranasal route. 
Work in mice was successfully shown to deliver TNF-α siRNA into rodent miRNA using 
a nanoemulsion technique. Another method to deliver RNA would be to interfere with  
the BBB using compounds such as mannitol 344,352 or noninvasive ultrasound technology 
353. Injecting miRNA directly into the brain is problematic due to ethical considerations 
as well as the surgical difficulties associated with it. However, work has been done in 
mice to successfully show this as a methodology to deliver RNA into the brain (354 and 
others). MiR-133 was delivered directly into the brain by injection, thereby 
circumventing issues such as BBB and brain region specificity 355.  
 In summary,  we continue to discover highly specfic miRNA targeting specfic 
proteins or pathways involved in neurodegeneration and AD, and also to devise ways to 
overcoming  various problems associated with miRNA delivery into the brain. Therefore, 
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while the delivery of miR-20b into the brain to reduce levels of APP faces many non-
trivial methodological challenges, the field is advancing rapidly, and a complete 
characterization of novel miRNAs, such as miR-20b, would facilitate a ready “pool” of 
miRNA that can be used to address AD pathology leading to a successful drug discovery.  
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